Method for treating parkinson's disease with blue photon therapy
Blue light therapy targeting ipRGC in the eye, combined with limited daytime sleep, effectively addresses non-motor symptoms in PD patients, improving sleep and mood with minimal side effects.
Patent Information
- Application Number
- PCT/EP2026/063576
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-05-11
- Publication Date
- 2026-11-19
AI Technical Summary
Current drug-based therapies for Parkinson's disease (PD) primarily focus on molecular targets in the brain, leading to limited effectiveness over time and significant side effects, while non-motor symptoms such as sleep disturbances and mood disorders remain challenging to treat effectively.
A twice-daily regimen of blue light therapy using a blue-photon emitting semiconductor composition, administered to the intrinsically photosensitive retinal ganglion cells (ipRGC) in the eye, combined with limited daytime sleep, to activate melanopsin and regulate circadian rhythms, is employed to treat non-motor symptoms.
This approach significantly improves sleep quality, reduces daytime sleepiness and depression, and enhances overall quality of life in PD patients with minimal side effects, as demonstrated by clinical trials.
Smart Images

Figure EP2026063576_19112026_PF_FP_ABST
Abstract
Description
[0001] METHOD FOR TREATING PARKINSON’S DISEASE WITH BLUE PHOTON THERAPY
[0002] TECHNOLOGICAL FIELD
[0003] The present invention relates to the field of therapy for patients suffering from non-motor symptoms such as patients with Parkinson’s Disease or other subjects suffering from sleep disorders or malfunctioning circadian rhythm. More in particular, the invention relates to light therapy methods wherein a blue-photon emitting composition is administered to the patient and therewith a dose of blue photons. The present invention also provides modalities for subjecting the patients to said therapy.
[0004] BACKGROUND
[0005] Hallmarks of neurodegenerative diseases are cognitive symptoms and motor symptoms. Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the coexistence of motor and nonmotor symptoms. PD affects 2-3% of the population >65 years of age [Poewe, W. etal., 2017], Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of a-synuclein are the neuropathological hallmarks of PD. Multiple other cell types throughout the central and peripheral autonomic nervous system are also involved, probably from early disease onwards. Although clinical diagnosis relies on the presence of bradykinesia and other cardinal motor features, PD is associated with many nonmotor symptoms that add to overall disability. Sleep disturbances are among the most common nonmotor symptoms, occurring in up to 90% of PD patients; these sleep disorders reduce quality of life and hamper daytime functioning. The treatment of sleep problems in PD remains challenging due to side effects of pharmacological treatments, namely, sleepiness, confusion, increased rate of falls, dizziness, and cognitive impairment. Although many different pharmacological and non-pharmacological strategies have been introduced to manage sleep problems in PD, their efficiency remains limited. Sleep medications often result in side effects and sometimes even in worsening of PD symptoms. Commonly used medicine are the dopamine precursor levodopa and sleep medication such as lorazepam, alprazolam, clonazepam, zopiclone and melatonin. Reported side effects of levodopa are nausea, dizziness, headache and somnolence. For the various sleep medicine, common side effects relate to, for example, respiratory depression, respiratory failure, seizures, dependency and abuse, hypotension, drowsiness, tiredness, dizziness, even sleep problems (insomnia), and also memory problems, poor balance or coordination, lethargy, sedation, drowsiness and motor impairment (impaired coordination, impaired balance, dizziness).
[0006] Therefore, PD patients are in an urgent need for improved therapies that address the devastating consequences of sleep disturbances and eventually adequately treat such nonmotor symptoms.SUMMARY
[0007] Parkinson’s disease (PD) is one of the most debilitating brain diseases. Despite the availability of symptomatic drug-based treatments, response towards the health of the PD patients remains scarce. The majority of PD patients, i.e. about 90% of patients, suffers from nonmotor symptoms with sleep disturbances being one of the most devastating and dominant conditions. Sleep disturbance is associated with bad sleep quality during night time, apparent as interrupted sleep, sleep apnoea, restless sleep, REM sleep disorder and insomnia. In addition, and highly related, PD patients suffer from sleepiness or tiredness during the day. Also mood disturbance is common as a consequence of such bad sleep quality, ultimately even expressed as anxiety and depression. Apart from nonmotor symptoms, some of the hallmark motor symptoms of PD are stiff muscles, tremors (shaking, typically in your hands or legs, that a PD patient is not able to control), problems with balance or coordination, and slow movements (bradykinesia). Although medical treatment of such nonmotor symptoms and / or motor symptoms of PD may provide relief for the PD patient to some extent, unfortunately, experiencing undesired side-effects ofthe treatment with current drug substances is rather common. Even side effects relating to non-optimal sleep quality and negative effects thereof during daytime are common, also affecting therapy compliance negatively. Current drug-based therapies predominantly focus on molecular targets in the cells of the brain, such as, for example, dopaminergic therapy, for which unfortunately effectiveness dampens in long-term treatment in PD patients. Daytime typically spans the period between awakening of a human subject in the morning and the moment at which the human subject goes to bed for a period of sleeping, typically during nighttime. For example, daytime spans the period between 7 a.m., when a human subject awakes and leaves the bed, and 11 p.m., when the human subject goes to bed for a period of rest and sleeping during nighttime, for example till 7 a.m. on the next day.
[0008] The current inventor, now however, established that a sophisticated dosage regimen of bluelight photons administrated by emission from a blue photon emitting semiconductor composition, is effective in providing almost complete relief from sleep disturbance related symptoms in PD patients. In addition, the PD patients are also relieved to a beneficial extent from motor symptoms of PD, such as bradykinesia, muscle stiffness, muscle rigidity, hypomimia (facial mask) and tremor. PD patients are very successfully subjected to a dosage regimen comprising administering twice daily a dose of bluelight photons relating to time and Melanopic Equivalent Daylight Illuminance ( M-EDI) at standardized moments during daytime, targeted delivered evenly to the sparsely present photoreceptor cells of the type intrinsically photosensitive retinal ganglion cells (ipRGC) in the eye’s retina ofthe PD patients, in combination with a very limited and restricted daytime sleep regimen both in moment at the time of day and in length, i.e. at most once daily sleep (also referred to as a power nap) for at most 20 minutes within the daytime period of noon till 2 pm. Patients subjected to the blue-light photons dosage regimen in combination with the stringent limited-access-to-daytime-sleep therapy experienced an overall surprisingly high improvement of their quality of life, both during night and during daytime. That is to say, subjecting PD patients to the new therapy including twice daily the activation of the photopigment melanopsin expressed on the surface of the ipRGC in the retina of the patient’s eye by contactingmelanopsin on the ipRGC cell surface with the blue-light photons emitted by a blue-light photon emitting composition (a semi-conductor composition, i.e. a LED), results in improved sleep quality during the night, even with fully undisturbed sleep for a large number of patients, and reduced sleepiness and tiredness during the day. In addition, initially present symptoms of depression before start of therapy disappeared almost completely for the PD patients upon adhering to the newly developed PD blue-light photon therapy with almost complete daytime sleep deprivation. PD patients suffering from depression, mood swings, sleepiness during daytime, bad sleep quality during night time, reported close to none side effects relating to the new therapy (only some mild effects were reported), whereas they reported a surprisingly high improvement of the primary outcome of the conducted randomized placebo-controlled clinical trial, i.e. a decrease in the Pittsburgh Sleep Quality Index (PSQI) score compared to the pre-treatment period, up to an effect size expressed as Pearson correlation coefficient (r; with a value running between 0 and 1) with value of 0,896. The effect size for sleepiness was even as high as 0.918 and for relief from depression the effect size was 0,556 (placebo control group: effect size of 0,088), due to subjecting the PD patients to the new therapy.
[0009] An aspect of the invention relates to a blue photon emitting composition for use in the treatment of a human subject suffering from any one or more of non-motor symptoms:
[0010] circadian rhythm disturbance;
[0011] sleep disturbance during nighttime;
[0012] sleepiness during daytime;
[0013] tiredness during daytime;
[0014] fatigue during daytime;
[0015] depressed mood or depression;
[0016] any combination of two - seven of these non-motor symptoms.
[0017] An aspect of the invention relates to a method of treating any one or more of non-motor symptoms in a human subject selected from:
[0018] circadian rhythm disturbance;
[0019] sleep disturbance during nighttime;
[0020] sleepiness during daytime;
[0021] tiredness during daytime;
[0022] fatigue during daytime;
[0023] depressed mood or depression;
[0024] any combination of two - seven of these non-motor symptoms,
[0025] wherein the method comprises the steps of:
[0026] (i) provision of a blue photon emitting composition for example a blue photon emitting composition as claimed and / or as detailed here below; and
[0027] (ii) administration of a therapeutically effective amount of blue photons emitted by the blue photon emitting composition to the retina of the eye(s) of the human subject by administration of the blue photon emitting composition in the proximity of the eye of the human subject therewith treating the one or more of non-motor symptoms in the human subject.An aspect of the invention relates to use of the blue photon emitting composition in the manufacture of a medicament for use in a method of treating any one or more of non-motor symptoms in a human subject:
[0028] circadian rhythm disturbance;
[0029] sleep disturbance during nighttime;
[0030] sleepiness during daytime;
[0031] tiredness during daytime;
[0032] fatigue during daytime;
[0033] depressed mood or depression;
[0034] any combination of two - seven of these non-motor symptoms,
[0035] wherein the method comprises the administration of a therapeutically effective amount of blue photons emitted by the blue photon emitting composition to the retina of the eye(s) of the human subject by administration of the blue photon emitting composition in the proximity of the eye of the human subject.
[0036] Based on the surprisingly effective treatment of the non-motor symptoms, it is evident that not only PD patients subjected to the blue photon dosing regimen benefits from the new therapy, but more in general any subject suffering from those non-motor symptoms.
[0037] Preferably, the human subject suffering from any one or more of the aforementioned non-motor symptoms suffers from any one or more selected from:
[0038] (1) a jet lag due to time zone travelling;
[0039] (2) non-motor symptoms due to previously having worked during nighttime or to working during nighttime;
[0040] (3) a neu rod egene rative disorder;
[0041] (4) Parkinson’s Disease (PD); or
[0042] (5) any combination of (1) - (4).
[0043] Most preferred, the human subject suffers from PD, i.e. is a PD patient. The PD patients were subjected to a twice daily blue-light photons administration regimen: a first dosage of blue-light photons was administered directly after awaking in the morning, that is to say, within 0 - 60 minutes after awaking. The administered dose was 45 minutes to 60 minutes administration of blue-light photons emitted at a M-EDI of 125 lux. PD patients were allowed to sleep once for at most 20 minutes during daytime, in between the period from noon till 2 pm. A second dose of blue-light photons was administered after at least 11 hours had lapsed after the end of the first dosage administration and the period within said second dosage was administered was in any occasion started no later than 2 hours before the start of the nighttime sleep period of the patient (‘bedtime”). The administered dose was again 45 minutes to 60 minutes administration of blue-light photons emitted at a M-EDI of 125 lux in the doubleblind randomized placebo-controlled clinical trial. For example, if a PD patient starts his / her night sleep at 11 pm, the second administration of the blue-light photons ended no later than at 9 pm. This way, the two doses separated at least 11 hours apart mimic a regular daytime with regular exposure to daylight. Melatonin production during daytime is effectively suppressed upon conducting the photon therapy with limited sleep period during daytime (at most one period of at most 20 minutes), with the strong result ofabsence of sleepiness, tiredness and depression for virtually all patients in the clinical trial. The peak wavelength of the emitted blue-light photons was 468 nm. Moreover, the treatment regimen also allows for a sleeping time during the night of at least 8 hours.
[0044] Beneficially, in the clinical trial, the blue photons emitting composition ( / .e. a blue-light source such as a semi-conductor composition such as a LED) was provided to the patient as a blue-light therapy applicator with an integrated blue light emitting composition, that is to say, the blue photon source is embedded in a glasses-like frame for positioning on the ears and nose of the PD patient. Herewith, a constant and stable positioning of the blue photons emitting composition (blue-light source) was made possible, with the administration of the blue-light photons at a substantially fixed distance relative to the melanopsin-bearing ipRGC in the retina, i.e. from a distance of about 1 ,5 cm when the distance between photon emission and the cornea of the patient’s eye is considered. In addition, by applying a light-guiding element in said frame, the blue-light photons are directed indirectly from the light source to the retina, and are directed to the melanopsin substantially evenly over the surface area of the ipRGC bearing retina. Since the number of ipRGC is relatively small, i.e. 0,5 - 2,0% of all ganglion cells in the human retina, and distributed over the retina surface area, it is beneficial to administer the blue-light photons efficiently to as many ipRGC as possible by efficiently distributed photons. The above-mentioned frame is configured to optimally deliver the blue-light photons over a large surface area of the retina, therewith activating the ipRGC during the therapy efficiently. The applied light-guiding element for dosing the blue photons is configured to deliver blue-light photons indirectly from the photon source from substantially above to the retina of the eye of the PD patient as photon bundles substantially directed to the parafoveal area of the retina and / or the perifoveal area and / or the optic disc (‘blind spot’) of the eye, that bear a relatively increased ipRGC density, as well as to deliver a diffuse evenly distributed bundle of blue photons contacting substantially the complete retina surface area and therewith all ipRGC present in the retina. Without wishing to be bound by any theory, by delivering blue photons at the ipRGC this way, efficient stimulation of the surface areas of the retina comprising the highest relative ipRGC density is achieved, whereas in addition by evenly emitting blue photons over the whole retina surface area aids in preventing saturation of rods is achieved by co-stimulation of the blue-light absorbing S-cones in the retina.
[0045] The inventor also developed an applicator configured for bringing a blue-photon emitting composition such as at least one LED in sufficient close proximity to the retina of the eye(s) of the human subject. Beneficially, the human subject who is wearing the applicator, is receiving a controlled dose of blue photons from a constant and controlled distance between the retina and the blue-photon emitting composition, contributing to sustained and constant efficacy of the blue-photon therapy, i.e. blue-light therapy. Administration of the blue photon emitting composition here refers to wearing the applicator on the nose and the ears of the human subject to whom a dose of blue photons is administered by emission of blue light from the blue photon emitting composition comprised by the applicator. The blue photon emitting composition in proximity to the eye(s) of the human subject here refers to a distance between the blue photon emitting composition and the outer surface of the eye of between 1 - 3 cm, preferably 1 ,5 cm ± 0,5 cm or about 1 ,5 cm. Preferably, the blue photons emitted by the blue photon emitting composition are directed to the retina of the eye(s) of the human subject such as a PD patientsubstantially from above. Herewith, entrance of blue light from natural daylight during a bright day is effectively mimicked. Preferably, part of the blue photons emitted by the blue photon emitting composition are entering the eye(s) and therewith triggering or activating melanopsin in the ipRGC of the retina of the eye(s) of the human subject, from below the eye(s). Herewith, a larger fraction of ipRGC in the retina is illuminated by the blue photons and therewith activated, amongst other benefits.
[0046] An aspect of the invention relates to a blue photon emitting composition for use in the treatment of a human subject wherein the human subject:
[0047] (1) has a jet lag due to time zone travelling;
[0048] (2) has worked during nighttime or is working during nighttime;
[0049] (3) is a neurodegenerative disorder patient;
[0050] (4) is a Parkinson’s Disease (PD) patient; or
[0051] (5) has / is any combination of (1) - (4), and preferably wherein the human subject is a patient with a neurodegenerative disorder, preferably the human subject is a PD patient,
[0052] wherein the human subject is suffering from any one or more of non-motor symptoms:
[0053] circadian rhythm disturbance;
[0054] sleep disturbance during nighttime;
[0055] sleepiness during daytime;
[0056] tiredness during daytime;
[0057] fatigue during daytime;
[0058] depressed mood or depression;
[0059] any combination of two - seven of these non-motor symptoms,
[0060] wherein at least one dose of blue photons is administered to ipRGC in the retina of the eye(s) of the human subject by emission of blue photons by the blue photon emitting composition.
[0061] An aspect of the invention relates to an applicator 1 comprising the blue photon emitting composition, for administration of photons to the eye(s) of the human subject, the applicator comprising a. two legs 7a, 7b for positioning the applicator 1 on the ears of the human subject, b. a support frame 9 comprising a support frame upper part 23 which is positioned above the eyes of the human subject when the applicator 1 is worn correctly, and which extents in between frame legs 7a, 7b of the applicator 1 , wherein at its center, the support frame upper part 23 is connected with a nose frame part 15,
[0062] c. at least one light source 51 , 53, L, L’ comprising the blue photon emitting composition, the light source integrated in the upper part 23 of the support frame 9 of the applicator 1 , and
[0063] d. a nose part 15 connected to the center of the upper portion 23 of the support frame 9 of the applicator 1 ,
[0064] wherein the applicator 1 is configured for direct and / or indirect administration of blue photons to the eye(s) of the human subject by administration of the blue-photon emitting composition when wearing the applicator 1 on the nose and on the ears (when the applicator 1 is worn correctly).Preferably, the direct and / or indirect administration of blue photons is from above to the eye(s) of the human subject.
[0065] Preferably, the blue photon emitting composition is a LED selected from a semi-conductor composition selected from any of:
[0066] gallium nitride (GaN);
[0067] wide-gap ll-VI semiconductor such as zinc selenide (ZnSe);
[0068] indium-gallium nitride (InGaN); and
[0069] p / n semiconductor composition consisting of a p-layer and an n-layer, wherein the p-layer and the n-layer are both InGaN.
[0070] Most preferred is a LED comprising or consisting of a p / n semiconductor composition consisting of a p-layer and an n-layer, wherein the p-layer and the n-layer are both InGaN. Applying such as blue-photon emitting composition resulted in the highly advantageous effects in the conducted single-armed double blind placebo-controlled trial with PD patients suffering from depression, sleep disturbance, affected circadian rhythm, daytime sleepiness or fatigue.
[0071] Preferably, the blue photon emitting composition is therefore provided by the applicator 1 and more preferably, the blue photon emitting composition is a p / n semiconductor composition consisting of a p-layer and an n-layer, wherein the p-layer and the n-layer are both InGaN.
[0072] An aspect of the invention is a kit of parts comprising the blue photon emitting composition, or comprising the applicator 1 comprising the blue photon emitting composition, and further comprising a leaflet with instructions for administering blue photons to the retina of the eye(s) of the human subject by wearing the applicator 1 (on the nose and ears of the human subject) and therewith administration of the blue photon emitting composition in the proximity of the eye of the human subject, or with instructions for administration of a therapeutically effective amount of blue photons emitted by the blue photon emitting composition to the retina of the eye(s) of the human subject by administration of the blue photon emitting composition in the proximity of the eye of the human subject by wearing the applicator 1 on the nose and ears of the human subject, for the treatment of the non-motor symptoms in the human subject.
[0073] An aspect of the invention is a kit of parts comprising the blue photon emitting composition and comprising a leaflet with instructions for administering blue photons to the retina of the eye(s) of the human subject, for example by wearing an applicator such as any of the applicators as detailed below and in the drawings Figures 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17 and 18, preferably the applicator 1 , and therewith administration of the blue photon emitting composition in the proximity of the eye of the human subject, or with instructions for administration of a therapeutically effective amount of blue photons emitted by the blue photon emitting composition to the retina of the eye(s) of the human subject by administration of the blue photon emitting composition in the proximity of the eye of the human subject for the treatment of the non-motor symptoms in the human subject, for example by wearing an applicator such as any of the applicators as detailed below and in the drawings Figures 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17 and 18, preferably the applicator 1 , on the nose and ears of the human subject.Preferred is the blue photon emitting composition for use, or the method, or the use, or the kit, as herein above described, wherein:
[0074] (i) the blue photons are administered to the ipRGC in the retina of the human subject substantially from above the eye(s) of the human subject; and / or
[0075] (ii) the blue photons are administered to the eye(s) of the human subject indirectly by the blue photon emitting composition; and / or
[0076] (iii) the blue photon emitting composition is administered to the eye(s) of the human subject by positioning the blue photon emitting composition in the proximity of the eye(s) of the human subject by wearing the applicator 1 on the nose and ears of the human subject; and / or (iv) the light emitted by the blue photon emitting composition has a wavelength of 460 - 480 nm; and / or
[0077] (v) two daily doses of blue photons are administered to the human subject; and / or
[0078] (vi) the first dose of blue photons administered during a day is administered to the human subject after awaking of the human subject in the morning, preferably within 0 - 60 minutes after awakening; and / or
[0079] (vii) the second dose of blue photons is administered to the human subject at least 11 hours after administration of a first dose of blue photons, or 11-15 hours after administration of a first dose of blue photons; and / or
[0080] (viii) the start of the dosing of the second administered dose of blue photons is no later than 2 hours before bedtime of the human subject; and / or
[0081] (ix) the blue photons are dosed by administering the first dose and the second dose each to the retina of the eye(s) of the human subject by emission of blue photons by the blue photon emitting composition for a duration of 20 minutes - 90 minutes; and / or
[0082] (x) the human subject sleeps during daytime after awakening in the morning for at most one time for 30 minutes or less; and / or
[0083] (xi) the human subject sleeps during daytime after awakening in the morning for at most one time between noon and 2 p.m.; or
[0084] any combination of (i) - (xi), or all of (i) - (xi).
[0085] BRIEF DESCRIPTION OF THE DRAWINGS
[0086] Fig. 1 shows a front perspective view of a blue-light therapy applicator;
[0087] Fig. 2 shows a rear perspective view of a blue-light therapy applicator;
[0088] Fig. 3 shows an exploded rearview of the blue-light therapy applicator shown in Figure 1 and 2;
[0089] Fig. 4 shows an exploded front view of the blue-light therapy applicator shown in Figure 1 and 2; Fig. 5 shows an exploded side view of the blue-light therapy applicator shown in Figure 1 and 2;
[0090] Fig. 6 shows a perspective rear view of a blue-light therapy applicator according to an alternative embodiment;Fig. 7 shows a perspective front view of a blue-light therapy applicator according to an alternative embodiment;
[0091] Fig. 8 shows a perspective rear view of a blue-light therapy applicator according to an alternative embodiment;
[0092] Fig. 9 shows an exploded rearview of the blue-light therapy applicator shown in Figure 7 and 8;
[0093] Fig. 10 shows an exploded front view of the blue-light therapy applicator shown in Figure 7 and 8; Fig. 11 A shows an exploded side view of the blue-light therapy applicator shown in Figure 7 and 8 Fig. 11 B shows side view of the light guiding elements 25, 26 in Figure 11 A;
[0094] Fig. 12A shows side view of light guiding elements 50 according to an alternative embodiment;
[0095] Fig. 12B shows a perspective front view of light guiding elements 50 according to an alternative embodiment;
[0096] Fig. 12C shows top view of light guiding elements 50 in Figure 12A and 12B;
[0097] Fig. 12D shows side view of light guiding elements 50 in Figure 12A-C as well as the support frame side 35 facing an eye and bearing a reflecting side 39;
[0098] Fig. 12E shows as an alternative embodiment a side view of light guiding elements 25, 26 in Fig. 11A, comprising an additional protruding portion 59, compared with the light guiding element of Fig. 11B, as well as the support frame side 35 facing an eye and bearing a reflecting side 39;
[0099] Fig. 12E: shows as an alternative embodiment the side view of light guiding elements 25’, 26’ in Fig.
[0100] 11 A, now comprising a protruding portion 59 integrated in the light guiding element 25, 26 in Fig. 11 A, as well as the support frame side 35 facing an eye and bearing a reflecting side 39 in Fig. 9 ;
[0101] Fig. 12F: Front view of an alternative embodiment of the light guiding element 25, 26;
[0102] Fig. 12G: side view of the light guiding elements 25’, 26’ of Fig. 12F, where protruding portion 59 of the light guiding elements 50 of Fig. 12E is now integrated as protruding portion 70 of the light guiding element 25’, 26’;
[0103] Fig. 13: shows a rear perspective view of a blue-light therapy applicator according to an alternative embodiment when compared with the blue-light therapy applicator of Fig. 6;
[0104] Fig. 14 shows a nose frame part and light guiding elements 25, 26 configured as a single part according to an alternative embodiment.
[0105] Fig. 15 shows a perspective front view of an alternative embodiment of the applicator 1.
[0106] Fig. 16 shows the applicator 1 of Fig. 15 in an upper view of the applicator 1.
[0107] Fig. 17 shows a perspective front view of an alternative embodiment of the applicator 1.
[0108] Fig. 18 shows the applicator 1 of Fig. 17 in a front view.
[0109] DEFINITIONS
[0110] The term “blue-light” has its regular meaning and here refers to light in the visible spectrum of light having wavelengths ranging from 400 to 500 nm or from 450 to 495 nm when the blue-light spectrum outside the shorter ultra-violet wavelength is referred to specifically.
[0111] The term “red-light” has its regular meaning and here refers to light with a wavelength of 660 nm to 700 nm.The term “blue light photon” or “blue photon” has its regular meaning and here refers to photons with a photon energy ranging from 3,10 eV (corresponding to a wavelength of 400 nm) and 2,48 eV (corresponding to a wavelength of 500 nm).
[0112] The term “blue-light photons emitting semiconductor composition” or “blue photon emitting composition” has its regular meaning and here refers to a composition capable of emitting blue photons in the 400 - 500 nm spectrum, preferably 440 - 485 nm or 460 - 480 nm. Examples of such compositions are a LED based on a semi-conductor composition such as GaN, ZnSe, or a p / n semiconductor composition consisting of a p-layer and an n-layer, wherein the p-layer and the n-layer are indium-gallium nitride (InGaN), and the phosphorescent coating of a fluorescent lamp and LED based on an organic molecule.
[0113] The term “applicator” has its regular scientific meaning and here refers to an object that can be wearable like a frame or glasses on the nose of a human subject with a nose part and on the ears of the subject with two legs. The applicator can have various alternative forms compared to conventional glasses having spectacle glasses. Throughout the application, the terms applicator, frame and glasses are used interchangeably when referring to the blue-light therapy applicator, unless specified otherwise.
[0114] The term “light therapy”, which may also be called phototherapy or bright light therapy, as used herein refers to the exposure of a subject to direct sunlight or artificial light at controlled wavelengths in order to treat a variety of medical disorders, including seasonal affective disorder (SAD), circadian rhythm sleep-wake disorders, cancers, neonatal jaundice, and skin wound infections. In the context of the invention light therapy is used to administer the light to the eye or to the eyes of the subject, preferably to ipRGC in the retina of the eye(s) of the human subject.
[0115] The term “blue-light therapy” as used herein refers to a method wherein a blue light (or blue photons) is administered to the patient by using a blue-light emission source and therewith administering a dose of blue photons. Said blue-light source may be a source emitting said blue light and / or said source may include an element for predominantly reflecting (such as a reflector), guiding (such as a light guiding element) or directing blue light or blue photons in response to an emitted (blue photon comprising) light beam. For example, said source comprises a light emitting source and a blue photon reflecting element. Said incident light beam may be a blue light or may be a light beam comprising said blue light and other wavelengths. For example, a portion of said emitted light beam may be reflected, wherein said reflected portion contains or consists essentially of said blue light or blue photons.
[0116] The term “subject” as used herein refers to a human suffering from or at risk of a certain health-related disorder, such as a disease or other pathological condition. The terms “subject” and “patient” are used interchangeably herein.
[0117] The term ’’treatment” as used herein has its conventional meaning and refers to a medical intervention or management of a subject with the intention to cure, ameliorate, or stabilise a health-related disorder. The term “treatment” includes e.g. active treatment that is a type of an action directed specifically toward the improvement of a health-related disorder, and also includes causal treatment that is a treatment directed towards a removal of the cause of the associated therewith health-related disorder. The terms “prevention” and “prophylaxis” as used herein are to be construed as referring to amedical intervention or management of a subject with the intention to maintain health or the normal bodily functions and / or prevent the otherwise anticipated development of a health-related disorder.
[0118] The term “amelioration” as used herein is to be construed as the process of improving or alleviating the severity, symptoms and / or progression of a disease or medical condition. It does not necessarily imply a cure, but implies to enhance the patient's quality of life, well-being and reduce the disease’s impact on daily functioning.
[0119] As used herein the term “administration” is to be construed as referring to the way of providing a substance, such as a compound, or a composition to a subject. Conversely, as used herein the term “delivery” is to be construed as referring to the way a compound or compositions reaches its destination site, e.g. specific zone or proximity to an organ, organ, its sub-compartment, cell or tissue type, for example the eye, the cornea of the eye, the lens of the eye, the retina of the eye, the ipRGC in the retina of the eye, the melanopsin on the ipRGC in the retina of the eye, the parafovea, the perifovea, the blind-spot of the eye, the nasal quadrant of the eye, the ventral-nasal-posterior are of the retina, etc. Administration can relate to e.g. contacting a composition or bringing in close proximity (< 2 cm) with the eye or other way of providing one or more substances (compounds) or composition onto or into the subject’s eye, with an intended delivery of the composition to e.g. ipRGC or melanopsin expressing cells as the destination site. Usually, the terms “administering” or “administration” will be construed as relating to the provision of a substance or compositions that is physiologically and / or pharmacologically useful (e.g. medicament) to treat or prevent a disease or a pathological condition in the subject. In the context of the present invention, emission of blue photons by the blue-photon emitting composition such as a semiconductor composition such as a LED, is also construed as administration of blue photons by the administration of the blue-photon emitting composition to the (proximity of the) eye of the human subject.
[0120] As used herein, the term “approximately” or “about,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall within 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).
[0121] The terms first, second, third and the like in the description and in the claims, are used for distinguishing between for example similar elements, compositions, constituents in a composition, or separate method steps, and not necessarily for describing a sequential or chronological order. The terms are interchangeable under appropriate circumstances and the disclosed herein embodiments can operate in other sequences than described or illustrated herein, unless specified otherwise.
[0122] The term “comprising”, used in the claims, should not be interpreted as being restricted to, for example, the elements or the method steps or the constituents of a compositions listed thereafter; it does not exclude other elements or method steps or constituents in a certain composition. It needs to be interpreted as specifying the presence of the stated features, integers, (method) steps or components as referred to, but does not preclude the presence or addition of one or more other features, integers, steps or components, or groups thereof. Thus, the scope of the expression “a method comprising steps A and B” should not be limited to a method consisting only of steps A and B, rather with respect to thepresent disclosure, the only enumerated steps of the method are A and B, and further the claim should be interpreted as including equivalents of those method steps. The scope of the expression “a method comprising steps A and B” encompasses a method consisting of steps A and B, unless the context clearly requires otherwise. Thus, the scope of the expression “a composition comprising components A and B” should not be limited to a composition consisting only of components A and B, rather with respect to the present disclosure, the only enumerated components of the composition are A and B, and further the claim should be interpreted as including equivalents of those components. The scope of the expression “a composition comprising components A and B” encompasses a composition consisting of components A and B, unless the context clearly requires otherwise.
[0123] In addition, reference to an element or a component by the indefinite article "a" or "an" does not exclude the possibility that more than one of the element or component are present, unless the context clearly requires that there is one and only one of the elements or components. The indefinite article "a" or "an" thus usually means "at least one".
[0124] Daytime typically spans the period between awakening of a human subject in the morning and the moment at which the human subject goes to bed for a period of sleeping, typically during nighttime. For example, daytime spans the period between 7 a.m., when a human subject awakes and leaves the bed, and 11 p.m., when the human subject goes to bed for a period of rest and sleeping during nighttime, for example till 7 a.m. on the next day.
[0125] “Bedtime” can be defined as the moment at which the human subject goes to bed and lays down for a resting period of sleeping, typically during nighttime, and here preferably during nighttime.
[0126] The use of terms in brackets in the text, with the exception of chemical and / or mathematical formulae, usually means that the term within brackets specifies a possible option or a possible meaning and should thus not be considered limiting.
[0127] The embodiments as described herein can operate in combination and cooperation, unless specified otherwise. Furthermore, the various embodiments, although referred to as “preferred” or“e.g.” or “for example” or “in particular” and the like are to be construed as exemplary manners in which the disclosed herein concepts may be implemented rather than as limiting.
[0128] For all Figures, “Figure” and “Fig.” refer to the same.
[0129] It will be apparent to those skilled in the art, based on the present disclosure, that the main aspects of the invention, as defined here above and hereunder, are based on the same innovative concepts. The innovative concepts presented herein are here above and hereunder described with respect to particular embodiments. Unless stated otherwise and / or unless something else is apparent from the context, the particular embodiments described herein apply, indiscriminately, to each and every one of the aspects of the invention as defined herein. Particular embodiments described herein should be regarded as descriptive and not limiting beyond of what is described in the claims. The embodiments as described herein can operate in combination and cooperation, unless specified otherwise.
[0130] DETAILED DESCRIPTIONNeurodegenerative diseases have in common that retinal abnormalities are apparent in patients. For example, degeneration of human ipRGC (also referred to as melanopsin-expression retinal ganglion cells; m-RGC) is observed in retina of PD patients [Ortuno-Lizaran, I., et al., 2018], As a result, photoreceptor functioning relating to the melanopsin expressing ipRGC is hampered to a certain extent depending on the age of the patient and state of progression of the neurodegenerative disease such as PD. PD is the second most common neurological disorder, affecting about 10 million patients worldwide. As said, also for PD patients, melanopsin-related retinal cell dysfunction has been established [Steiner & de Zeeuw, 2024], This finding of disrupted ipRGC could be at the basis of circadian dysregulation in neurodegenerative diseases such as PD. That is because ipRGC function in entrainment of the circadian rhythm by transmitting light and dark information via the retinohypothalamic tract directly to the suprachiasmatic nucleus (SCN) that can be referred to as the internal clock of the human brain. That is to say, the ipRGC are part of the non-image forming pathways that primarily control and measure light irradiance detection. Melanopsin, an opsin protein containing a vitamin A-based chromophore maximally sensitive at 479 nm, is the photopigment contained within ipRGC. Melanopsin-containing RGCs project to SCN and other CNS regions and regulate physiological and behavioral responses as important as circadian rhythms (sleep / wake cycles), melatonin production or mood [La Morgia, C., et al., 2017], In brief, the ipRGC constitute a small subset of regular RGC consisting of about 0,4-2% of the total. The ipRGC, thus, not only project to the SCN of the hypothalamus synchronizing circadian rhythms to the light-dark cycle, but also play an important role in non-visual functions of the eye, regulating sleep through the connections with the ventrolateral preoptic nucleus (VLPO) and the lateral hypothalamus (LH) and regulating melatonin secretion, and its suppression, through the connections with the pineal gland, for example.
[0131] Indeed, patients suffering from a neurodegenerative disease in general and, in particular, PD patients, suffer from non-motor symptoms such as sleep dysregulation, mood disturbances, fatigue, and circadian rhythms dysfunction (alteration in the circadian secretion pattern of melatonin). These symptoms can contribute to overall low quality of life due to amongst others depression (depressed mood), sleepiness and tiredness during daytime (fatigue), and insomnia during night-time. Dysfunction of circadian rhythms in PD is a cause of sleep disturbances also resulting in cognitive impairment and metabolic deficits, psychiatric problems and mood symptoms, or cardiovascular problems, negatively impacting quality of life. Since the ipRGC are involved in the control and regulation of processes such as sleep regulation, mood and circadian rhythms functioning, malfunctioning of ipRGC, decreased number of ipRGC or decreased extent of proper ipRGC functioning in patients can thus negatively influence the well-being of the patient relating to the above-mentioned symptoms. Functional impairment of ipRGC in PD is likely the result of dying ipRGC and / or loss of melanopsin in the ipRGC. The main type of ipRGC in the human retina, the Mid cells, is most affected in PD patients, similar to what is observed in the elderly (function of age). The ipRGC malfunctioning is at the basis of the circadian rhythm disorders, normally accompanied by sleep disruption, and may accelerate the progression of neurodegenerative disease pathology, also in PD. Non-synchronized circadian rhythms and disturbed dopamine release are likely contributing to the observed pathology and negatively affected quality of life of patients. The circadian dysfunction in PD patients presents as one or more of the following: (1)Abnormal melatonin rhythm; (2) Abnormal rest-activity rhythm and flattening of daily activity. (3) Abnormal blood pressure (and heart rate rhythm abnormalities; (4) Abnormal temperature and cortisol rhythm; (5) Abnormal clock gene rhythmicity in peripheral blood cells; (6) Circadian fluctuations of motor symptoms with a worsening of motor functions possibly related to the dopamine level variations over the day [La Morgia, C., etal., 2017],
[0132] With loss of ipRGC and / or loss of proper functioning of ipRGC, it may appear challenging to direct PD therapy to ipRGC, for the purpose of improving circadian rhythm synchronization, sleep disturbance, daytime sleepiness and / or tiredness and sub-optimal mood conditions such as suffering from depression. The more, since the number of ipRGC in a healthy human subject’s eye retina is already relatively low with reported numbers of less than 2%, less than 1 ,5% or even less than 1% of the total ganglion cell population in the retina. Nevertheless, the inventor overcame the disadvantage of the even declining number of blue-light photon sensitive target cells by combining blue-light therapy with sleep training therapy, and by testing the combination in a double-blind, placebo-controlled, randomized clinical trial with PD patients. The therapy for neurodegenerative disease, in particular the PD therapy, comprising:
[0133] (1) selecting the appropriate blue light emitting semiconductor composition for emitting wavelength for the selected blue-light photons;
[0134] (2) selecting an applicator configured to allow controlled administration of the blue-light photons emitting semiconductor composition to the retina of the eye of the patient suffering from a neurodegenerative disorder such as PD, for delivering of a dose of blue photons at the ipRGC cells bearing the blue-photon activable melanopsin protein, controlled administration here referring to for example the combination of duration of administration, amount of emitted blue light, direction of emitted blue light by the semiconductor composition relative to the surface of the retina in the eye of the patient with the neurodegenerative disease such as PD;
[0135] (3) determining and selecting the appropriate duration of the administration of the blue-light photons to the ipRGC as well as the frequency (twice daily; 5 minutes - 2 hours, for example 20 minutes - 90 minutes, or 30 minutes - 75 minutes, or 45 minutes - 60 minutes, or any time therein between such as 100, 80, 70, 50, 40, 35, 25, 15 or 10 minutes);
[0136] (4) determining and selecting the appropriate timing of the start of the first daily dosage (directly after awakening in the morning, that is to say preferably within 1 hour after awakening, for example administering the blue-light photon source for the first daytime dosing of blue-light photons in the morning within 0 - 60 minutes after awakening, such as within 50, 45, 40, 35, 30, 25, 20, 15, 10, 5, 2, 1 minutes after awakening, or any time in between);
[0137] (5) determining and selecting the appropriate dosage interval (at least 11 hours during daytime, for example 11 , 12, 13, 14, 15 hours, or any time in between, since the end of administering the blue-light photon emitting composition for the first daytime dosing of blue-light photons in the morning after awakening);
[0138] (6) determining and selecting the appropriate timing and start of the second daily dose (administration of the blue-light photons terminating not later than 2 hours before the start of the sleep cycle of the (PD) patient), allowing a sleep cycle during night-time of at least 8 hours;(7) allowing the patient, e.g. the PD patient, to sleep only once at most 20 minutes during daytime in between the two day-time administrations of the blue-light emitting composition, and only at the time of the day between 11 am and 3 pm, preferably between noon and 2 pm;
[0139] (8) avoidance of wearing sunglasses or the like during the twice-daily administration of the bluelight photons emitting composition; preferably, not wearing spectacle glasses or the like at all, therewith allowing exposure of the retina to as much daylight as possible; therewith even more preferably, not wearing glasses or the like during administration of the photon source and being outside in the daylight during the administration of the two doses, if possible at the time of dosing.
[0140] Of interest, ipRGC cell-density and decline of the number of (properly functioning) ipRGC in the retina of patients suffering from neurodegenerative disease such as PD are not evenly distributed over the surface of the eye’s retina. In PD, axonal loss, or retinal nerve fiber layer thinning, is apparent to a higher extent in the infero-temporal quadrants of the optical nerve, whereas in the nasal quadrant extent of axonal loss is minimal [La Morgia, C., et al., 2017], With axonal loss taken as a measure for still present and remaining proper functioning ipRGC that are available for administration of blue-light photon source, therewith allowing directing blue-light photons to the melanopsin on the ipRGC surface, this finding may serve as a guidance for to which quadrant of the human retina the blue-light therapy could at least be beneficially directed: the nasal quadrant of the retina of the PD patient, for example, in addition to, or as an alternative to, directing the light therapy to the parafoveal area of the retina and / or the perifoveal area and / or the optic disc (‘blind spot’) of the eye. The highest density of the ipRGC is located in the parafoveal area circumscribing the fovea, and the perifoveal area circumscribing the parafoveal area, with approximately 15-40 ipRGC per square millimeter [Mure, L.S., et al., (2019); Hannibal, J., et al. (2017)]. Since all axons of ipRGC converge to the optic disc, corresponding to the physiological blind spot, directing light therapy with blue light (~440 - 500 nm; melanopsin sensitivity for light peaks at blue light with wavelength 480 nm) at least at the blind spot provides the opportunity to activate the vast majority of ipRGC present and still active in the neurodegenerative disease patient such as a PD patient. Furthermore, ipRGC density is about 10 ipRGC per square millimeter in the nasal quadrant (posterior nasal retinal surface area of the eye). Without wishing to be bound by any theory, relative cell density of the type or types of ipRGC involved in circadian entrainment, e.g. ml, is higher in the areas of the retina that are at least, and preferably, treated with the doses of blue-light photons by administering the blue-light photon emitting composition such as a semi-conductor material, for example LED.
[0141] Based on these combined findings, the inventor selected the application of blue-light photons to melanopsin bearing ganglion cells by administration of the blue light source (the blue-light photons emitting semiconductor composition), here the semi-conductor composition (a LED), emitting the bluelight photons in a way such that it is ensured that at least all of the areas of the retina where the presence of properly functioning ipRGC is maximal, are dosed with the blue-light photons emitted by the blue-light source. The applied applicator, here glasses-like frame with optional spectacle glasses, or the glasses, ensures the delivery of blue-light photons to at least the peri-foveal region, the parafoveal region, the blind spot as well as the nasal quadrant (posterior nasal retinal surface area of the eye), with in additionalso delivery of blue-light photons to the melanopsin in the ipRGC located in the remainder and additional locations of the retina and in fact to the whole retina surface area bearing ipRGC. This way of administration ensures the maximal chance for therapy efficacy when the dosing of the blue-light photons by administering the blue-light photon source to the retina of the patient is considered. Therapy efficacy is apparent when applying the clinical protocol as herein disclosed, even when the number of properly functioning ipRGC has declined due to progression of neurodegenerative disease such as PD and also under influence of the ageing patient in general, since ageing as such is accompanied with a decline of ipRGC functioning.
[0142] An aspect of the invention relates to a blue photon emitting composition for use in the treatment of a human subject suffering from any one or more of non-motor symptoms:
[0143] circadian rhythm disturbance;
[0144] sleep disturbance during nighttime;
[0145] sleepiness during daytime;
[0146] tiredness during daytime;
[0147] fatigue during daytime;
[0148] depressed mood or depression;
[0149] any combination of two - seven of these non-motor symptoms.
[0150] Preferred is said use wherein the human subject suffers from PD.
[0151] An aspect of the invention relates to a method of treating any one or more of non-motor symptoms in a human subject selected from:
[0152] circadian rhythm disturbance;
[0153] sleep disturbance during nighttime;
[0154] sleepiness during daytime;
[0155] tiredness during daytime;
[0156] fatigue during daytime;
[0157] depressed mood or depression;
[0158] any combination of two - seven of these non-motor symptoms,
[0159] wherein the method comprises the steps of (i) provision of the blue photon emitting composition, preferably provision of a blue photon emitting composition as herein described, more preferably, provision of an applicator 1 comprising the blue photon emitting composition; and (ii) administration of a therapeutically effective amount of blue photons emitted by the blue photon emitting composition to the retina of the eye(s) of the human subject by administration of the blue photon emitting composition in the proximity of the eye of the human subject, therewith treating the one or more of non-motor symptoms in the human subject.
[0160] Preferred is said method of treatment wherein the human subject suffers from PD.
[0161] An aspect is the use of the blue photon emitting composition in the manufacture of a medicament for use in a method of treating any one or more of non-motor symptoms in a human subject:
[0162] circadian rhythm disturbance;sleep disturbance during nighttime;
[0163] sleepiness during daytime;
[0164] tiredness during daytime;
[0165] fatigue during daytime;
[0166] depressed mood or depression;
[0167] any combination of two - seven of these non-motor symptoms,
[0168] wherein the method comprises the administration of a therapeutically effective amount of blue photons emitted by the blue photon emitting composition to the retina of the eye(s) of the human subject by administration of the blue photon emitting composition in the proximity of the eye of the human subject.
[0169] In an embodiment of the invention, the human subject is subjected to or suffers from any one or more of:
[0170] (1) a jet lag due to time zone travelling;
[0171] (2) having worked during nighttime or is working during nighttime;
[0172] (3) a neu rod egene rative disorder;
[0173] (4) Parkinson’s Disease (PD); or
[0174] (5) any combination of (1) - (4).
[0175] Preferred is said use wherein the human subject suffers from PD.
[0176] An aspect of the invention relates to a blue photon emitting composition for use in the treatment of a human subject suffering from any one or more of:
[0177] (1) a jet lag due to time zone travelling;
[0178] (2) having worked during nighttime or is working during nighttime;
[0179] (3) a neu rod egene rative disorder;
[0180] (4) Parkinson’s Disease (PD); or
[0181] (5) any combination of (1) - (4).
[0182] An aspect of the invention relates to a method of treating (in a human subject) any one or more of:
[0183] (1) a jet lag due to time zone travelling;
[0184] (2) having worked during nighttime or is working during nighttime;
[0185] (3) a neu rod egene rative disorder;
[0186] (4) Parkinson’s Disease (PD); or
[0187] (5) any combination of (1) - (4),
[0188] wherein the method comprises the steps of (i) provision of the blue photon emitting composition, preferably provision of a blue photon emitting composition as herein described, more preferably, provision of an applicator 1 comprising the blue photon emitting composition; and (ii) administration of a therapeutically effective amount of blue photons emitted by the blue photon emitting composition to the retina of the eye(s) of the human subject by administration of the blue photon emitting composition in the proximity of the eye of the human subject.Preferred is said method of treatment wherein the human subject suffers from PD.
[0189] An aspect is the use of the blue photon emitting composition in the manufacture of a medicament for use in a method of treating (in a human subject) any one or more of:
[0190] (1) a jet lag due to time zone travelling;
[0191] (2) having worked during nighttime or is working during nighttime;
[0192] (3) a neu rod egene rative disorder;
[0193] (4) Parkinson’s Disease (PD); or
[0194] (5) any combination of (1) - (4),
[0195] wherein the method comprises the administration of a therapeutically effective amount of blue photons emitted by the blue photon emitting composition to the retina of the eye(s) of the human subject by administration of the blue photon emitting composition in the proximity of the eye of the human subject.
[0196] Preferred is said use wherein the human subject suffers from PD.
[0197] An aspect of the invention relates to an applicator comprising a light source or a blue photon emitting composition, for use in administration of blue photons to an eye of a human subject, wherein the use comprises one or more of:
[0198] treating any one or more of non-motor symptoms in a human subject:
[0199] circadian rhythm disturbance;
[0200] sleep disturbance during nighttime;
[0201] sleepiness during daytime;
[0202] tiredness during daytime;
[0203] fatigue during daytime;
[0204] depressed mood or depression;
[0205] any combination of two - seven of these non-motor symptoms; and / or treating in a human subject any one or more of:
[0206] (1) a jet lag due to time zone travelling;
[0207] (2) having worked during nighttime or is working during nighttime;
[0208] (3) a neu rod egene rative disorder;
[0209] (4) Parkinson’s Disease (PD); or
[0210] (5) any combination of (1) - (4).
[0211] Preferred is said use wherein the human subject suffers from PD.
[0212] In particular embodiments, said human subject is suffering from Parkinson’s disease and wherein by said use at least one of the symptoms of Parkinson’s Disease selected from bradykinesia, pain, akinesia, sleep disturbance, depressed mood, sadness, melatonin levels during daytime and dystonia is prevented or treated, is delayed and / or reduced, and / or wherein by said use at least one or more of the symptoms of circadian rhythm disturbance, sleep disturbance during nighttime, sleepinessduring daytime, tiredness during daytime, fatigue during daytime, depressed mood or depression; is delayed and / or reduced.
[0213] In a preferred embodiment, said applicator comprising the blue photon emitting composition, for administration of blue photons to the eye(s) of the human subject, the applicator comprising
[0214] a. two legs 7a, 7b for positioning the applicator 1 on the ears of the human subject, b. a support frame 9 comprising a support frame upper part 23 which is positioned above the eyes of the human subject when the applicator 1 is worn correctly, and which extents in between frame legs 7a, 7b of the applicator 1 , wherein at its center, the support frame upper part 23 is connected with a nose frame part 15,
[0215] c. at least one light source 51 , 53, L, L’ comprising a light source or the blue photon emitting composition, and
[0216] d. a nose part 15 connected to the center of the upper portion 23 of the support frame 9 of the applicator 1 ,
[0217] wherein the applicator 1 is configured for direct and / or indirect administration of blue photons to the eye(s) of the human subject, optionally by administration of the blue-photon emitting composition, when wearing the applicator 1 on the nose and on the ears (when the applicator 1 is worn correctly).
[0218] In embodiments of the invention the human subject suffers from any one or more selected from:
[0219] circadian rhythm disturbance;
[0220] sleep disturbance during nighttime;
[0221] sleepiness during daytime;
[0222] tiredness during daytime;
[0223] fatigue during daytime;
[0224] depressed mood or depression;
[0225] any combination of two - seven of these non-motor symptoms.
[0226] Preferably, the blue photon emitting composition is provided as an integrated part of an applicator 1 comprising the blue photon emitting composition such as a semi-conductor composition such as a LED.
[0227] For example, administration of the blue photon emitting composition in the proximity of the eye of the human subject is established by wearing an applicator 1 comprising the blue photon emitting composition on the ears and the nose of the human subject, therewith positioning the blue photon emitting composition at a distance of about 1 - 2 cm above the eye(s) of the human subject.
[0228] PATIENTS SUFFERING FROM NON-MOTOR SYMPTOMSThe clinical trial conducted with PD patients revealed that the non-motor symptoms were treated effectively: the extent of the symptoms was decreased to a highly convenient and beneficial extent, or one or more of the symptoms were completely absent upon subjecting the human subject to the new therapy comprising the new blue-photon dosing regimen in combination with minimal sleep during daytime (at most once for at most 20 minutes only within the time frame between noon and 2 p.m.). In addition, motor symptoms also improved for the PD patients in that stiffness, tremor and rigidity decreased. Mainly because the positive effect on sleep-related non-motor symptoms and the positive effect on circadian rhythm was highly apparent in the PD patients, it is shown by the blue-photon therapy regimen that also human subjects other than PD patients benefit from being subjected to the new bluephoton dosage regimen.
[0229] Therefore, in embodiments of the invention the human subject has any one or more selected from:
[0230] (1) a jet lag due to time zone travelling;
[0231] (2) worked during nighttime or is working during nighttime;
[0232] (3) a neu rod egene rative disorder;
[0233] (4) Parkinson’s Disease (PD); or
[0234] (5) any combination of (1) - (4).
[0235] That is to say, the human subject who is suffering from any one or more of the listed non-motor symptoms can suffer from PD, can be a neurodegenerative disease or disorder patient, and / or can suffer from a jet lag and / or from e.g. a disturbed circadian rhythm due to e.g. staying awake late in the evening, perhaps combined with sleep deprivation by early (forced) awakening in the next morning, or due to time zone traveling or night shift work (working during evening and / or night hours, while sleeping during daytime), etc., etc.
[0236] For example, the human subject benefitting from being subjected to the administration of a dose of blue photons according to the newly designed dosage regimen is a PD patient who has been diagnosed with idiopathic PD according to UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria with Hoehn & Yahr stage 2-4. For example, the human subject is a PD patient suffering from sleep disorder as determined based on the Pittsburg Sleep Quality Index Score (PSQI) and / or suffering from excessive daytime sleepiness (EDS) defined by the Epworth Sleepiness Scale (ESS). For example and preferably, PD patients who score PSQI of 5 or more and / or who have an ESS score of 7 or more, and therewith are considered as PD patients having sleep disorder, are subjected to the inventive new therapy, i.e. the blue-photon dosage regimen applying administration of the bluephoton emitting composition therewith administering the required doses of blue photons with the efficient duration and within the established and controlled time frame of the day.
[0237] In a preferred embodiment, the human subject is a patient, such as a PD patient, suffering from sleep disorder, as determined based on the Pittsburg Sleep Quality Index Score (PSQI), of > 10 and / or suffering from excessive daytime sleepiness (EDS), defined by the Epworth Sleepiness Scale (ESS), of > 10, and is subjected to the inventive new therapy to reduce the Pittsburg Sleep Quality Index Score (PSQI) and or to reduce the Epworth Sleepiness Scale (ESS) of said human subject. It has been shown that by use of the blue light therapy of the invention that the Pittsburg Sleep Quality Index Score (PSQI)is reduced to less than 10, such as 8 or less, and / or the excessive daytime sleepiness (EDS) is reduced as defined by the Epworth Sleepiness Scale (ESS) to less than 10, such as 9 or less.
[0238] In a preferred embodiment, the PD patient subjected to the blue-photon administration by administering the blue-photon emitting composition is also administered a pharmaceutical substance or composition, for example selected from: levodopa, a dopamine agonist, a selective monoamine oxidase type B (MAO-B) inhibitor, an anticholinergic agent, amantadine, or any combination of two or more of such pharmaceuticals. Such one or more pharmaceuticals can be administered prior to the start of administering the first dose of blue-photons by administration of the blue-photon emitting composition, and in addition can also still be administered during the blue-photon therapy.
[0239] Due to the surprisingly large extent of improvement in non-motor symptoms for the PD patients who were subjected to the blue-photon dosage regimen, it is part of the invention that the PD patients are administered a lower dose of the one or more pharmaceuticals during and / or after treatment with the new blue-photon dosage regimen than the dose of such one or more pharmaceuticals that was administered to the PD patients prior to the start of being subjected to the new blue-photon dose regimen. Especially, the dose is lowered of the one or more pharmaceuticals that were previously administered for treating or lowering non-motor symptoms that are effectively treated or lowered upon subjecting the PD patient to the new blue-photon dosage regimen. Preferably, administration of such one or more pharmaceuticals is halted completely during and / or after subjecting the PD patient to the new blue-photon dosage regimen.
[0240] BLUE PHOTON DOSAGE REGIMEN
[0241] As said, the inventor established a new blue-photon dosage regimen beneficial for lowering or even completely treating effectively the non-motor symptoms from which PD patients with a.o. sleep problems suffer. Apart from PD patients, also human subjects suffering from the same or similar non-motor symptoms such as disturbed circadian rhythm and / or sleep problems, sleepiness during the day, fatigue and / or depressed mood (depression) or anxiety, benefit from being subjected to the blue-photon dosage regimen by administering blue photons by administering the blue-photon emitting composition. Without wishing to be bound by any theory, the melanopsin on the surface of the ipRGC in the retina of the human subject is the blue-photon absorbing cellular surface protein, therewith being involved in the signalling cascade ultimately resulting in the observed improved effects on sleep, circadian rhythm, tiredness during the day, depression, etc. Therefore, in an embodiment, at least one dose of blue photons is administered to ipRGC in the retina of the eye(s) of the human subject by emission of blue photons by the blue photon emitting composition. The inventor established that dosing blue photons twice a day to the human subject is efficacious and enough for achieving the ground-breaking improved effects on non-motor symptoms. In addition, also motor symptoms in PD patients improved upon subjecting the PD patients twice daily to the blue-photon dosage regimen.Preferred is the embodiment, wherein the dose of blue photons is administered twice daily to the human subject.
[0242] PD patients, and in fact any human subject suffering from the above-listed non-motor symptoms, have an improved quality of life when the time at sleep during nigh time is at least 6 hours, preferably at least 7 hours, more preferably at least 8 hours, preferably less than 10 hours, more preferably less than 9 hours, such as for example 7 hours, 7 hours 30 minutes, 8 hours, 8 hours 30 minutes, or any time in between 6 hours and 10 hours, preferably about 8 hours such as 8 hours ± 15 minutes. In order for allowing such an optimized period of sleep during night time, the mimicking of exposure to day light during day time is achieved by administering the blue-photon emitting composition and therewith administering the blue photons to the retina of the eye(s) of the human subject, twice daily during day time with an interval of at least 11 hours. The blue-photon dosage regimen performs optimally when the second dose of blue photons is administered up to at latest 2 hours before start of sleeping during night time by the human subject. Thus, in an embodiment a second dose of blue photons is administered to the human subject at least 11 hours after administration of a first dose of blue photons, or 11-15 hours after administration of a first dose of blue photons. Preferred is the embodiment, wherein the second and last dose of blue photons that is administered during day time is administered starting no later than 2 hours before bedtime of the human subject.
[0243] As an example, when a human subject starts night time sleep at 11 p.m., the end of the administration period of the second daily dose of blue photons by administration of the blue-photon emitting composition, should be no later than 9 p.m. Preferably, the human subject sleeps for about 8 hours till about 7 a.m. in the next morning, starting with a next cycle of the blue photon dosage regimen after awakening. For an optimal efficacious blue-photon therapy, administration of the blue-photon emitting composition should be executed shortly after awakening in the morning after ending the 8-hours period of sleep during night time.
[0244] Preferred is the embodiment, wherein the first dose of two daily doses administered during day time of blue photons is administered to the human subject after awaking of the human subject in the morning (before noon, preferably before 10 a.m., more preferably before 9 a.m., even more preferably before 8 a.m. and preferably after 6 a.m., more preferably after 7 a.m.), preferably within 0 -60 minutes after awakening, or within 50, 45, 40, 35, 30, 25, 20, 15, 10, 5, 2, 1 minutes after awakening, or any time in between. Practically, the administration of the blue-photon emitting composition for administering the first daily dose of blue photons starts as soon as feasible when awaking in the morning.
[0245] Without wishing to be bound by any theory, adaptation of the circadian rhythm to exposure of the melanopsin in the ipRGC in the retina of the eye(s) of the human subject to blue photons requires an exposure time of minutes to hours for efficient activation of the neuronal pathways involved in said adaptation. Similar for the neuronal response to blue photon illumination of the ipRGC relating to sleep / wake cycles, onset of melatonin production and sleep quality. This, in contrast to the relatively much faster response of rods and cones to visible light when neuronal processing relating to vision is considered (milliseconds to seconds time scale). Therefore, for an efficacious effect of exposing ipRGC in the retina to a blue-light emitting composition, such exposure to blue photons should last also at minimum for a few minutes. Good effects on adjusting disturbed circadian rhythm, adjusting disturbedsleep / wake cycle, improving sleepiness, depression, fatigue, tiredness, etc., are now achieved by the inventor by administration of the blue-photon emitting composition and therewith the administration of the blue photons, for at least 5 minutes. That is to say, the duration of administering a single dose of blue photons last for at least 5, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 75, 80, 90, 100, 105, 110, 120 minutes, preferably any time period selected from 20 - 90 minutes, more preferably 25 - 75 minutes, even more preferably 30 - 60 minutes such as 30, 45 or 60 minutes, during a single dose administration.
[0246] A preferred embodiment relating to time for dosing a single dose of blue photons is when the blue photons are dosed by administering at least the first dose by emission of blue photons by the blue photon emitting composition for a duration of 5 minutes - 2 hours, or 20 minutes - 90 minutes, or 30 minutes - 75 minutes, or 45 minutes - 60 minutes, or any time therein between or 100, 80, 70, 50, 40, 35, 25, 15 or 10 minutes, and / or by administering at least the second dose by emission of blue photons by the blue photon emitting composition for a duration of 5 minutes - 2 hours, or 20 minutes - 90 minutes, or 30 minutes - 75 minutes, or 45 minutes - 60 minutes, or any time therein between or 100, 80, 70, 50, 40, 35, 25, 15 or 10 minutes, or by administering the first dose and the second dose by emission of blue photons by the blue photon emitting composition for a duration of 5 minutes - 2 hours, or 20 minutes - 90 minutes, or 30 minutes - 75 minutes, or 45 minutes - 60 minutes, or any time therein between or 100, 80, 70, 50, 40, 35, 25, 15 or 10 minutes.
[0247] Preferably, duration of the first and second daily blue-photon dose is 30 minutes or 45 minutes or 60 minutes, more preferably 30, 45 or 60 minutes ± 5 minutes.
[0248] Human subjects, such as PD patients, suffering from the hereabove listed non-motor symptoms such as sleepiness, fatigue, tiredness during day time, in many occasions sleep at least once during day time, in many occasions at least 30 minutes. For example, PD patients sleep during day time 1-5 times for, for example, 30 minutes - 2 hours, due to the extent of the non-motor symptoms. As an effect and consequence, the perhaps already to a certain extent disturbed sleep / wake cycle and / or the perhaps already to a certain extent disturbed circadian rhythm get further disturbed due to the relatively excessive day time sleep periods. In addition, due to for example depression or day-time tiredness, human subjects such as PD patients, suffering from the non-motor symptoms tend to stay inside their house, avoiding going outside into the day light. Of course, also due to the sleeping time during day time, said human subjects are exposed less to natural day light. Limited daily exposure to day light also contributes to disturbance of circadian rhythms and / or disturbance of sleep / wake cycle. It is now due to the surprisingly effective blue-photon treatment protocol designed by the inventor and proven in the clinical trial, that it has been established that the non-motor symptoms are lowered in extent or treated completely by subjecting the human subjects to the newly designed blue-photon dosage regimen. Effects are even improved when the human subjects refrains from sleeping more than once during day time. When the human subjects only sleep once during day time, in combination with the twice-daily administration of the blue-photon emitting composition, sleep quality improved during night time and sleepiness, depression, tiredness, disturbed motor function during day time declined or even disappeared. That is to say, the at most once-daily period of sleeping during day time should be in between the first dosing of blue photons and the second dosing of blue photons.By applying the blue-photon dosage regimen, the downward spiral of parameters negatively strengthening the outcome of other parameters, is broken. That is to say, sleeping more and more during day time, resulting in being exposed less and less to natural day light, negatively effects circadian rhythm more and more and / or negatively effects sleep / wake cycles more and more. Due to adapting to the bluephoton therapy, the human subject sleeps less, if at all anymore, during day time, and due to less sleepiness, tiredness, depressed mood during day time, the human subject tends to go outside into the natural daylight more frequently, resulting in beneficial (further) improvement of the circadian rhythm and sleep / wake cycles, and as a consequence thereof, results in improved sleep quality during night time, which has a further positive outcome on quality of life during day time due to even less tiredness and sleepiness, etc.
[0249] In a preferred embodiment, the human subject sleeps during daytime after awakening in the morning for at most one time for 0 minutes - 60 minutes, or 10 minutes - 45 minutes, or 20 minutes -30 minutes, or 0 - 20 minutes. Preferably, the human subject sleeps during day time (and in between the twice daily administrations of the blue-photon emitting composition) only once for 15 - 45 minutes, preferably less than 30 minutes, more preferably about 20 minutes such as 20 minutes ± 5 minutes or at most 20 minutes. Most preferably, the human subject does not sleep at all during the period between awaking in the morning and starting sleeping during night time, and therewith does not sleep at all in the period in between the administration of the two daily dosages of blue photons. Therewith, the beneficial effects of the blue-photon therapy are apparent while quality of life during day time is for example also improved due to optimized length of day time for executing for example social activities, mental or physical exercise, work activities, household activities, leisure activities, etc., etc. Less sleepiness, tiredness, fatigue during day time (and night time due to improved sleep quality and length) and less depressed mood (or even complete cure from depression) contribute to improved quality of life for the human subject such as a PD patient.
[0250] Optimally, the at most one power nap or short period of sleep during day time is about at midday, about at half the time period in between two administrations of blue photons. That is to say, the inventor achieved good results when the human subjects subjected to the blue photon therapy slept for at most one time for at most 20 minutes between noon and 2 p.m. Preferred is the embodiment, wherein the human subject sleeps during daytime after awakening in the morning for at most one time between 11 a.m. and 3 p.m., more preferred any time between noon and 2 p.m.
[0251] To the surprise of the inventor, the new blue photon therapy provided already highly beneficial improvements relating to the non-motor symptoms and even motor symptoms within a short time frame of a few weeks of subjecting the human subjects, here PD patients, to the administration twice daily of the blue-photon emitting composition and therewith the twice daily administration of blue photons to the retina of the eye(s). That is to say, after 2 weeks since the start of subjecting human subjects to the new blue-photon dosage regimen, positive effects on sleepiness, tiredness, depression, sleep quality were already apparent. Surprisingly, said improvements were still apparent when therapy was halted and parameters were assessed 3 weeks later since last dosing. Since the PD patients did not or at most very minimally experience any side effects of therapy, continuous treatment is highly beneficially possible for the human subjects. Therefore, preferred is the embodiment, wherein the treatment lastsfor at least 2, 3, 4, 5, 6 days, or at least 1 week, at least 2 weeks, at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 weeks, or any period therein between, or at least 4, 5, 6, 7, 8, 9, 10, 11 months, or at least 1 , 2, 3, 4, 5 years, or for the rest of the life time of the human subject. Also preferred is the embodiment, wherein the treatment is provided as repeating cycles of a first cycle comprising a first treatment period followed by a first interval period without treatment of at least 2, 3, 4, 5, 6 days, or at least 1 week, at least 2 weeks, at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 weeks, or any period therein between, followed by at least a second cycle comprising a second treatment period and a subsequent second interval period. For example, a human subject can be subjected to 5-28 cycles of twice-daily administration of the blue photons, followed by a period of 7-90 days without the blue-photon therapy, whereafter a new cycle of a period with daily therapy and a period without daily therapy follows. Such cycle scheme can be established for the human subject based on the duration of (sufficient) beneficial effect of daily therapy once daily therapy is halted. Start of a new cycle of twice-daily administration of blue photons is then started when non-motor symptoms increase in strength to an unpleasant and undesired level for the human subject such as a PD patient, or re-appear when completely absent due to earlier treatment cycle(s).
[0252] Therefore, a blue photon emitting composition for use in the treatment of a human subject suffering from any one or more of non-motor symptoms:
[0253] circadian rhythm disturbance;
[0254] sleep disturbance during nighttime;
[0255] sleepiness during daytime;
[0256] tiredness during daytime;
[0257] fatigue during daytime;
[0258] depressed mood or depression;
[0259] any combination of two - seven of these non-motor symptoms,
[0260] is preferred, wherein the human subject
[0261] (1) has a jet lag due to time zone travelling;
[0262] (2) has worked during nighttime or is working during nighttime;
[0263] (3) is a neurodegenerative disorder patient;
[0264] (4) is a Parkinson’s Disease (PD) patient; or
[0265] (5) has / is any combination of (1) - (4), and preferably is a patient with a neurodegenerative disorder, preferably the human subject is a PD patient,
[0266] wherein at least one dose of blue photons is administered to ipRGC in the retina of the eye(s) of the human subject by emission of blue photons by the blue photon emitting composition, wherein the dose of blue photons is administered twice daily to the human subject, wherein a second dose of blue photons is administered to the human subject at least 11 hours after administration of a first dose of blue photons, or 11-15 hours after administration of a first dose of blue photons,wherein the last dose, which is the second dose after awakening, of blue photons administered during a day is administered starting no later than 2 hours before bedtime of the human subject, wherein the first dose of blue photons administered during a day is administered to the human subject after awaking of the human subject in the morning, preferably within 0 - 60 minutes after awakening,
[0267] wherein the blue photons are dosed by administering at least the first dose by emission of blue photons by the blue photon emitting composition for a duration of 5 minutes - 2 hours, and / or by administering at least the second dose by emission of blue photons by the blue photon emitting composition for a duration of 5 minutes - 2 hours, or by administering the first dose and the second dose by emission of blue photons by the blue photon emitting composition for a duration of 5 minutes -2 hours,
[0268] wherein the human subject sleeps during daytime after awakening in the morning for at most one time for 0 minutes - 60 minutes,
[0269] wherein the human subject sleeps during daytime after awakening in the morning for at most one time between 11 a.m. and 3 p.m., or between noon and 2 p.m.
[0270] Therefore, according to an aspect of the invention, a blue photon emitting composition for use in the treatment of a human subject is preferred wherein the human subject
[0271] (1) has a jet lag due to time zone travelling;
[0272] (2) has worked during nighttime or is working during nighttime;
[0273] (3) is a neurodegenerative disorder patient;
[0274] (4) is a Parkinson’s Disease (PD) patient; or
[0275] (5) has / is any combination of (1) - (4), and preferably wherein the human subject is a patient with a neurodegenerative disorder, preferably the human subject is a PD patient,
[0276] wherein the human subject is suffering from any one or more of non-motor symptoms:
[0277] circadian rhythm disturbance;
[0278] sleep disturbance during nighttime;
[0279] sleepiness during daytime;
[0280] tiredness during daytime;
[0281] fatigue during daytime;
[0282] depressed mood or depression;
[0283] any combination of two - seven of these non-motor symptoms,
[0284] wherein at least one dose of blue photons is administered to ipRGC in the retina of the eye(s) of the human subject by emission of blue photons by the blue photon emitting composition, wherein the dose of blue photons is administered twice daily to the human subject,wherein a second dose of blue photons is administered to the human subject at least 11 hours after administration of a first dose of blue photons, or 11-15 hours after administration of a first dose of blue photons,
[0285] wherein the last dose, which is the second dose after awakening, of blue photons administered during a day is administered starting no later than 2 hours before bedtime of the human subject, wherein the first dose of blue photons administered during a day is administered to the human subject after awaking of the human subject in the morning, preferably within 0 - 60 minutes after awakening,
[0286] wherein the blue photons are dosed by administering at least the first dose by emission of blue photons by the blue photon emitting composition for a duration of 5 minutes - 2 hours, and / or by administering at least the second dose by emission of blue photons by the blue photon emitting composition for a duration of 5 minutes - 2 hours, or by administering the first dose and the second dose by emission of blue photons by the blue photon emitting composition for a duration of 5 minutes -2 hours,
[0287] wherein the human subject sleeps during daytime after awakening in the morning for at most one time for 0 minutes - 60 minutes,
[0288] wherein the human subject sleeps during daytime after awakening in the morning for at most one time between 11 a.m. and 3 p.m., or between noon and 2 p.m.
[0289] Preferably, the blue photons are dosed by administering at least the first dose by emission of blue photons by the blue photon emitting composition for a duration of 20 minutes - 90 minutes, or 30 minutes - 75 minutes, or 45 minutes - 60 minutes, or any time therein between or 100, 80, 70, 50, 40, 35, 25, 15 or 10 minutes, and / or by administering at least the second dose by emission of blue photons by the blue photon emitting composition for a duration of 20 minutes - 90 minutes, or 30 minutes - 75 minutes, or 45 minutes - 60 minutes, or any time therein between or 100, 80, 70, 50, 40, 35, 25, 15 or 10 minutes, or by administering the first dose and the second dose by emission of blue photons by the blue photon emitting composition for a duration of 20 minutes - 90 minutes, or 30 minutes - 75 minutes, or 45 minutes - 60 minutes, or any time therein between or 100, 80, 70, 50, 40, 35, 25, 15 or 10 minutes.
[0290] Preferably, the human subject sleeps during daytime after awakening in the morning for at most one time during 5 minutes - 60 minutes, or 10 minutes - 45 minutes, or 20 minutes - 30 minutes, or during 5 - 20 minutes. Preferably, the human subject does not sleep during daytime. This means that the human subject stays awake between the awakening, typically in the morning, and
[0291] Preferably, the treatment lasts for at least 2, 3, 4, 5, 6 days, or at least 1 week, at least 2 weeks, at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 weeks, or any period therein between, or at least 4, 5, 6, 7, 8, 9, 10, 11 months, or at least 1 , 2, 3, 4, 5 years, or for the rest of the life time of the human subject. When the human subject suffers from a neurodegenerative disorder or a neurological disorder, preferably Parkinson’s Disease, said human subject is preferably treated for the rest of the life time of the human subject.For a human subject who has a jet lag due to time zone travelling and / or who has worked during nighttime or is working during nighttime, it is preferred that the treatment lasts for at least 2, 3, 4, 5, 6 days, or at least 1 week, at least 2 weeks, at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 weeks, or any period therein between, or at least 4, 5, 6, 7, 8, 9, 10, 11 months, or preferably for as long as the human subject suffers from any one or more of non-motor symptoms:
[0292] circadian rhythm disturbance;
[0293] sleep disturbance during nighttime;
[0294] sleepiness during daytime;
[0295] tiredness during daytime;
[0296] fatigue during daytime;
[0297] depressed mood or depression;
[0298] any combination of two - seven of these non-motor symptoms.
[0299] For a human subject suffering from any one or more of non-motor symptoms:
[0300] circadian rhythm disturbance;
[0301] sleep disturbance during nighttime;
[0302] sleepiness during daytime;
[0303] tiredness during daytime;
[0304] fatigue during daytime;
[0305] depressed mood or depression;
[0306] any combination of two - seven of these non-motor symptoms,
[0307] preferably due to the human subject having a jet lag due to time zone travelling, or the human subject having worked during nighttime or is working during nighttime, it is preferred that the treatment lasts for at least 2, 3, 4, 5, 6 days, or at least 1 week, at least 2 weeks, at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 weeks, or any period therein between, or at least 4, 5, 6, 7, 8, 9, 10, 11 months, or at least 1 , 2, 3, 4, 5 years.
[0308] For a human subject suffering from any one or more of non-motor symptoms: circadian rhythm disturbance;
[0309] sleep disturbance during nighttime;
[0310] sleepiness during daytime;
[0311] tiredness during daytime;
[0312] fatigue during daytime;
[0313] depressed mood or depression;
[0314] any combination of two - seven of these non-motor symptoms,
[0315] preferably due to the human subject being a neurodegenerative disorder patient,
[0316] it is preferred that the treatment lasts for at least 2, 3, 4, 5, 6 days, or at least 1 week, at least 2 weeks, at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 weeks, or any period therein between, orat least 4, 5, 6, 7, 8, 9, 10, 11 months, or at least 1 , 2, 3, 4, 5 years, or for the rest of the life time of the human subject.
[0317] Preferably, the treatment lasts for the rest of the life time of the human subject, and / or preferably a PD patient.
[0318] BLUE PHOTON EMITTING COMPOSITION
[0319] The blue photon emitting composition is for example and preferably a light emitting diode (LED) selected from an inorganic LED or an organic LED.
[0320] Preferably, the inorganic LED is selected from a semi-conductor composition selected from any of: gallium nitride (GaN);
[0321] wide-gap ll-VI semiconductor such as zinc selenide (ZnSe);
[0322] indium-gallium nitride (InGaN); and
[0323] p / n semiconductor composition consisting of a p-layer and an n-layer, wherein the p-layer and the n-layer are both InGaN,
[0324] More preferably, the blue photon emitting composition is a p / n semiconductor composition consisting of a p-layer and an n-layer, wherein the p-layer and the n-layer are both InGaN.
[0325] Preferably, the organic LED is selected from any of:
[0326] 9,10-bis (2-naphthyl )-2-t-butyl anthracene (TBADN);
[0327] 9,10-bis (2-naphthyl) anthracene (ADN);
[0328] diaryl anthracene;
[0329] di(styryl)arylene;
[0330] fluorene; and
[0331] pyrene,
[0332] although application of an inorganic semi-conductor material such as the / n semiconductor composition consisting of a p-layer and an n-layer, wherein the p-layer and the n-layer are both InGaN is preferred.
[0333] It is preferred that the blue photon emitting composition is a LED that is a wide band-gap semiconductor composition of the direct transition type with an energy band gap of 2.6 eV or larger.
[0334] In preferred embodiments, the light emitting diode is a blue-light emitting LED comprising as a photon source a p / n semiconductor composition, preferably a p / n semiconductor composition consisting of a p-layer and an n-layer, consisting of an InGaN p-layer and an InGaN n-layer. That is to say, it is preferred that the photon source is a p / n semiconductor composition consisting of a p-layer and an n-layer wherein the p-layer and the n-layer are gallium-nitride (GaN) or alloys thereof such as aluminum-gallium nitride (AIGaN) and InGaN, preferably the p-layer and the n-layer are InGaN. Indium gallium nitride (InGaN, lnxGai-xN) is a p / n-semiconductor material made of a mix of gallium nitride (GaN) and indium nitride (InN), known in the art. It is a ternary group 11 l / group V direct bandgap semiconductor. Preferred is the photon source that is a p / n semiconductor composition consisting of a p-layer and an n-layer wherein the p-layer and the n-layer are GaN or alloys thereof such as AIGaN and InGaN, preferably the p-layerand the n-layer are InGaN, wherein the p-layer is doped with magnesium and the n- layer is doped with silicon, preferably the p-layer is InGaN doped with magnesium and the n-layer is InGaN doped with silicon.
[0335] APPLICATOR FOR ADMINISTERING BLUE-PHOTON EMITTING COMPOSITION
[0336] An applicator 1 according to a first embodiment of the invention is shown in Figure 1-5, and according to a second embodiment of the invention is shown in Figure 7-11 A, 12F, and according to a third embodiment of the invention is shown in Figure 6, 13. The applicator 1 comprises two legs 7a, 7b and support frame 9 with the support frame upper part 23 extending between these two legs 7a, 7b. A nose part 15 is connected to the center of the upper portion 23. Alternatively or in addition, the nose part 15 can comprise a nose support 15' connected to the nose part 15 of the applicator 1 as shown in Figure 2. The nose support 15' provides comfort to the subject when wearing the applicator 1 on the ears and the nose. Optionally, the nose support 15' is adjustable by the human subject according to the nose of the subject which provides a better fit of the applicator 1 to the subject when being worn. The applicator 1 further comprises a frame-like structure 5 which is at least an assembly of two legs 7a, 7b, the upper portion 23 of support frame 9 and a nose part 15. The frame-like structure 5 forms an opening 3a’, 3b’ below the upper portion 23 and encloses only partially the perimeter of said opening(s) 3a’, 3b’ positioned in front of the eyes of the subject. Said openings 3a’, 3b’ in front of the eyes of the subject provide free sight for the subject even when wearing the applicator 1.
[0337] Alternatively, said openings 3a’, 3b’ can support spectacle glasses 3a, 3b (Fig. 1) or 3a”, 3b” (Fig. 12F) which are preferably transparent or could also be coloured. Alternatively, said spectacle glasses 3a, 3b or 3a”, 3b” are filter lenses for filtering of blue light and / or UV light or for filtering of red light. The spectacle glasses 3a, 3b are optionally releasably connected to the frame-like structure 5, such that the subject can exchange the filter lenses for filtering blue light and / or UV light for filter lenses for filtering red light, or, when desired, for conventional spectacle glasses, or even more preferably, the spectacle glasses 3a, 3b are removed, for example before the start of a blue-light therapy cycle comprising emission of blue photons by the semi-conductor composition capable of emitting blue light and comprised by the frame-like structure 5 of the applicator 1 , the composition for example being a LED.
[0338] The inventor has identified that the daylight when combined with the blue photons administered by applying the applicator 1 , and therewith applying the blue-photon emitting composition, further improved the outcome of the blue-light therapy. Therefore, in a preferred embodiment, the applicator 1 and / or the frame 5 is provided without any optional conventional lenses and / or spectacle glasses 3a, 3b, which spectacle glasses, when present, could reduce the intensity of daylight coming onto the eye of the subject, and more specifically, the retina.
[0339] The frame-like structure 5 connected at a first extremity 11 (left extremity in Figure 1) with a first side part 12 and connected at a second extremity 13 (right extremity in Figure 1) with a second side part14. The side parts 12, 14 are connected to frame legs 7a, 7b at an extremity distal from the frame-like structure 5.
[0340] The applicator 1 is for example provided with two light sources (not shown), wherein the first light source in the first side part 12 is incorporated into an extremity thereof located near the first opening 3a’ configured for receiving a spectacle glasses 3a, whereas the second light source in the second side part 14 is incorporated into an extremity thereof located near the second opening 3b’ for receiving a spectacle glasses 3b.
[0341] In addition, the applicator 1 is optionally provided with a soft lining 40 for enhancing the comfort of the wearer of the applicator 1. Then, it is possible to provide at least the sides of the lining that are facing the eyes as reflecting lining in order to reflect the incident indirect light from the light guiding elements 25, 26 on said sides of the lining, when in use, to the eyes.
[0342] Figure 2 shows the light guiding elements 25, 26, 50 positioned in the upper part 23 of support frame 9 of the applicator 1. As shown in Figures 2-11 A, the support frame upper part 23 of the glasses 1 is provided with two plate-shaped elongated light guiding elements 25, 26 integrated therein. The light emitted by the blue-photon emitting composition, here LEDs, is guided indirectly to the eyes with the light guiding elements 25, 26. An extremity 27, 29 of each light guiding element 25, 26, that is directed away from the nose frame part 15, is in connection with the LEDs in the frame side parts 12, 14 such that the artificial light of the LEDs is emitted indirectly to the eyes from above via the plate-shaped light guiding elements 25, 26 integrated in the support frame upper part 23 of the support frame 9. It is possible that in the applicator 1 no artificial light is emitted directly from a LED to the eyes of a user (human subject who wears the applicator on the ears and the nose), such that the administration of blue photons by applying the applicator 1 is only using indirect blue light. This way, for the wearer (human subject) the comfort of the applicator 1 during a blue-light treatment is enhanced. In one embodiment, the surface of the plate-shaped elongated light guiding element that faces downwardly, when the applicator 1 is worn, is only transparent for photons at one or more discrete portions of said surface. This way, photons delivered by the blue-photon source comprised by the light source in the applicator 1 (blue-photon emitting composition provided as a LED integrated as a light source in the applicator 1), can be directed to predetermined portions of the retina of the eye of the wearer of the applicator 1. In an alternative embodiment, the complete surface of the plate-shaped elongated light guiding element that faces downwardly, when the applicator is worn, is transparent for blue photons. This way, the blue photons emitted by the blue photon source (blue-photon emitting material) comprised by the light source in the applicator 1 are delivered efficiently to the eye and the retina of the wearer of the applicator 1 over the whole length of the light guiding element located above the eye of the wearer of the applicator 1 , with less loss of energy (blue photons) when compared to a partially non-transparent light guiding element.
[0343] Figure 6 and 13 show an embodiment of the applicator 1 of the invention, wherein the nose frame part 15 and the light guiding elements 25 and 26 form a unit 28 with a nose frame part and two light guiding elements. Figure 14 shows such a unit 28 with a nose frame part and two light guiding elements, wherein the separate parts building up unit 28, namely the nose frame part 15 and the light guiding elements 25 and 26, are indicated. In unit 28 with a nose frame part and two light guidingelements the nose frame part 15 connects the light guiding elements 25 and 26 such that a single part is formed. The application of the unit 28 with a nose frame part and two light guiding elements in an applicator 1 alternative to a nose frame part 15 and light guiding elements 25 and 26, is optional.
[0344] The sides of the support frame 9 that are facing the eyes of the wearer and that are positioned below the light guiding elements 25, 26, 50, such as for example the nose frame side portion 17, reflect the artificial light that is coming indirectly from the light guiding elements 25, 26, 50 to the eye of the user. The other sides of the support frame 9 located below the light guiding elements 25, 26, 50, that are facing the eye when in use, can be provided in the same manner as the nose frame side portion 17, such that the amount of light emitted to the eyes is increased. These sides of support frame 9 comprise support frame sides 35, 36 facing the eyes, which extents in the applicator 1 between the nose frame side portion 17 and the support frame upper part 23 of the support frame 9. The reflecting sides of the support frame 9 can comprise inner surfaces that surround the openings 3a’, 3b’, such as the inner surface 16 of the nose frame part and the other inner surfaces 38, 39 of the support frame 9 located below the light guiding elements 25, 26, 50.
[0345] In addition, the applicator 1 is provided with a soft lining 40 for enhancing the comfort of the wearer of the glasses 1 . Then, it is possible to provide at least the sides of the lining that are facing the eyes as reflecting lining in order to reflect the incident indirect light from the light guiding elements 25, 26, 50 on said sides of the lining, when in use, to the eyes.
[0346] The light reflecting parts of the applicator 1 , such as the inner surface 39 of the support frame 9 located below the light guiding elements 25, 26, 50 and / or the lining, reflect the incident light for at least 50%, preferably for more than 85%.
[0347] With the applicator 1 comprising the blue-photon emitting composition it is possible to project 100 M-EDI lux at minimum at the level of the retina, for example between 125 M-EDI lux and 400 M-EDI lux, or for example 200 M-EDI lux to 300 M-EDI lux, and 225 M-EDI lux at minimum and 275 M-EDI lux at maximum at the level of the eye, for example about 250 M-EDI lux.
[0348] The Figure 12E shows another embodiment of the light guiding element 25, 26. The elongated light guiding element 25, 26 is provided with a first LED (similar to LED 51 shown in Fig. 12B), as well as with a second LED 53 (similar to LED 51 shown in Fig. 12B). For executing a blue-light treatment, with the light guiding element 25, 26 no further light sources are required in the applicator 1. The elongated light guiding element 25, 26 is provided with The surface of the protruding portion 59 faces the eye of the wearer of the applicator as well as faces surface 39 located below the light guiding element at the bottom side of the opening 3a’, 3b’ in support frame side 35 facing the eyes (Figure 12E). The artificial light emitted by the blue-photon emitting composition (LED) in the direction of surface 39 indicated by arrows P3” and P4” is reflected by the reflector 39 facing towards the lens of the eye due to tilt angle beta relative to the horizontal between bottom side b and upper side c of the support from side 35 when the applicator 1 is worn by the human subject (see Figure 12D), said reflection of blue light indicated with arrows P6”.
[0349] The Figures 12A, B, C, D show another embodiment of the light guiding element 50. Figure 12A shows a side view, Figure 12C shows a top view of the light guiding element 50. This light guiding element 50 can be assembled in the support frame upper part 23 of the support frame 9 of the applicator1 shown in Figures 1-11A and 13 at the same position as the light guiding element 25, 26. The side portion defined between e and f is facing the eye of the human subject wearing the applicator and said side portion can be curved such that the light guiding element 50 has a concave shape from the view point of the wearer of the applicator when the side portion e - f is considered. This way, bundles of emitted blue photons by the light guiding element are directed to the cornea and the lens of the eye of the wearer.
[0350] The elongated light guiding element 50 is provided with a first LED 51 , as well as with a second LED 53. For executing a blue-light treatment, with the light guiding element 50 no further light sources are required in the applicator 1. The elongated light guiding element 50 is provided with an upper side 57 partly provided with notches 55, as well as a portion 59 protruding at the bottom side 61. The surface of the protruding portion 59 faces the eye of the wearer of the applicator as well as faces surface 39 located below the light guiding element at the bottom side of the opening 3a’, 3b’ in support frame side 35 facing the eyes (Figure 12D; side view of light guiding element 50). The artificial light emitted by the blue-photon emitting composition (LED) in the direction of surface 39 indicated by arrows P3 and P4 is reflected by the reflector 39 facing towards the lens of the eye due to tilt angle beta relative to the horizontal between bottom side b and upper side c of the support from side 35 when the applicator 1 is worn by the human subject, said reflection of blue light indicated with arrows P6. The artificial light emitted by the blue-photon emitting composition (LED) 51 , 53 is also directed towards the lens of the eye of the human subject wearing the applicator, due to the protruded shape of portion 59 at the bottom side 61 of the light guiding element, indicated with arrows P3, P4, said protruded shape resulting in an angle alpha (see Figure 12E for the same relative positions) between surface a - b of portion 59 and the horizontal. Herewith, the surface of 59 points in the direction of the lens of the eye as well as towards the surface 39 located below the eye. Directing light bundles P3, P4 and P6 to the lens of the eye of the wearer from different directions results in a evenly irradiated retina surface area therewith maximizing the number of ipRGC irradiated with the blue light emitted from the LEDs.
[0351] The portions of upper side 57 located nearby the LEDs 51 , 53 are flat without notches 55. The notches 55 are provided between the flat portions of the upper side. The portion with notches 55 is larger than the two flat end-portions together. The notches 55 extend transversely to the longitudinal direction of the elongated light guiding element 50. The cross-section of each notch 55 is triangular. The notches 55 become evenly deeper toward the second LED 53, while the distance between the centers 63 of the consecutive notches remains constant.
[0352] The LEDs 51 , 53 emit the artificial blue light substantially laterally in the light guiding element 50 in the direction indicated by the arrows P1 and P2 to the notches 55. The artificial blue light is reflected by the notches 55 in the direction indicated by arrows P3 and P4 to the eye of a user.
[0353] In one embodiment, the surface of the flat portion 59 of the elongated light guiding element that faces downwardly (bottom side 61), when the applicator is worn, is only transparent for blue photons at one or more discrete portions of said surface. This way, blue photons delivered by the blue photon emitting composition comprised by the light source in the applicator 1 , can be directed to predetermined portions of the eye and to predetermined portions of the retina of the eye of the wearer of the applicator. In an alternative embodiment, the complete surface of the flat portion 59 of the elongated light guidingelement 50 that faces downwardly (bottom side 61), when the applicator 1 is worn, is transparent for blue photons. This way, the blue photons emitted by the blue photon source comprised by the light source in the applicator are delivered efficiently to the eye and the retina of the wearer of the applicator 1 over the whole length of the light guiding element 50 located above the eye of the wearer of the applicator 1 , with less loss of energy (blue photons) when compared to a partially non-transparent light guiding element 50.
[0354] The light guiding element 50 is preferably made of polycarbonate (e.g., ALCOM pwl 10 / 1.1 WT1302-05LB). It is possible to add colored or light reflective pigments to the material so that the light can be reflected to the eyes diffusely.
[0355] Figures 12F and 12G show a portion of an alternative embodiment relating to the applicator 1 . Figure 12F shows a front view of the applicator 1 , with the eye of the human subject wearing the applicator 1 behind the applicator. Figure 12G shows a side view of the applicator 1 , with the eye of the human subject wearing the applicator located at the left side of the applicator. The support frame 9 (with the support frame upper part 23 as shown in e.g. Figures 1 , 3) comprises integrated light sources L, L’ for emitting blue photons, therefore shown as dashed rectangles within support frame 9. The support frame 9 bears a first light guiding element 25’ corresponding to light guiding element 25, as well as a second light guiding element 26’ corresponding to light guiding element 26’, wherein the first and second light guiding elements 25’, 26’ also correspond to the spectacle glasses 3a, 3b. That is to say, functionally, the light guiding element 25, 26 and the spectacle glasses 3a, 3b are integrated, therewith providing the shown light guiding element 72. The front surface of light guiding element 72, pointing to the front in the orientation of Figure 12F, has a smaller surface area than the back surface 71 pointing towards the eye of the human subject wearing the applicator, and therewith the surface 70 connecting the front surface and the back surface of light guiding element 72 protruding backwardly in the orientation shown with the surface 70 pointing away from the eye of the wearer. Blue light emitted from light sources L, L’ (e.g. blue-photon emitting composition such as LED) in direction indicated with arrows L10, L11 , L12, L13 is bent into the direction of the lens of the eye of the human subject wearing the applicator, indicated by arrows L10’, L11’, L12’, L13’, here pointing backwardly. As a result, blue photons emitted by the blue-photon emitting composition comprised by light source L, L’ is provided to the retina of the eye of the human subject wearing the applicator from above the eye of the human subject and is provided indirectly from the light source to the retina. The spectacle glasses 3a”, 3b” are covering about half of the surface area of the eye of the human subject when wearing the applicator, being the top half of the surface area. The blue light indicated with arrows L10’, L11’, L12’, L13’ is entering the eye essentially horizontally and is illuminating at least the parafoveal and perifoveal surface area of the retina of the wearer.
[0356] The frame 5 is provided with a control unit such as a circuit board (PCB) and the frame 5 is provided with a battery. The battery that is comprised by the applicator 1 is for example a rechargeable lithium ion polymer battery known in the art, suitable for delivering power to the LEDs sufficient to provide blue photons with 125 - 500 M-EDI lux, for example 200 - 300 M-EDI lux, for example 250 M-EDI lux ± 25 M-EDI lux. Optionally, the frame 5 may be provided with a memory storage. These components may be located in the frame side portions 12, 14 or in the frame legs 7a, 7b. Further, the frame mayinclude a communication device (not shown) such as, for example, a USB port such as a microUSB port, for providing a wired connection and I or, for example, a Bluetooth chip for providing a wireless connection. The applicator 1 for example is provided with a battery having a voltage of at least 3,7 Volt, and having a capacity of at least 120 mAh. These battery specifications are sufficient and enough for generating a blue photon output with 125 to 250 M-EDI lux.
[0357] The applicator 1 may be part of a system further comprising an external device comprising a processor as well as a computer program which, in use, causes the processor to control the LEDs in the applicator 1 in accordance with a predetermined program.
[0358] It is possible that the applicator 1 is designed so that the support frame of the frame only partially encloses the perimeter of the openings 3a’, 3b’ configured for receiving spectacle glasses 3a, 3b.
[0359] It is also possible that at least portions of the surface of the support frame side facing the wearer's eye such as the inner surface 39 of the support frame 9 located below the light guiding elements 25, 26, 50, are designed such that the light to be reflected is diffused. Also, portions of the support frame facing the wearer's eye can be curved such that the light to be reflected is directed to a desired position in the eye. Further, the side of the support frame facing the wearer's eye may be provided with whitening agents.
[0360] It is further possible to provide the applicator 1 with at least a light source integrated centrally in the frame, for direct and I or indirect delivering light to the eyes substantially from above.
[0361] It has been found by the inventorthat blue photons are most efficiently provided to the retina of the eye of a wearer of the applicator 1 , when blue photons are delivered essentially from above the eye through the lens of the eye on the retina in the eye. Without wishing to be bound by theory, this observed highest efficiency is achieved since the light sensitive nerve cells of the retina (intrinsic photosensitive retinal ganglion cells) are predominantly located in the middle of the eye and at the nasal bottom side of the eye (when the wearer of the applicator 1 is in upright position). Furthermore, it has been found by the current inventor that melatonin production is efficiently suppressed in the host (human subject) wearing the applicator 1 when the at least one light source of the applicator 1 delivers about 125 - 250 M-EDI lux at the level of the lens of the eye of the wearer.
[0362] Preferably, the applicator 1 comprises as a light source four blue light emitting LEDs, for example each such a LED having a power of about 0,1 Watt. Preferably, such LEDs comprise a photon source capable of emitting blue photons with an emission peak wavelength of about 468 nm.
[0363] The frame 5 can be provided with two hinging frame legs. In the position of use of the applicator 1 with unfolded hinging frame legs, the applicator 1 can be worn by a human subject, such that each opening 3a’, 3b’ with optional spectacle glass 3a, 3b is positioned in front of one of the two eyes of a human subject aided by frame 5 for positioning on the ears and nose of the human subject. By hinging the frame legs towards each other in the direction of the openings 3a’, 3b’, the applicator 1 is brought from the unfolded state to a compact folded state, such that it is stored, for example, in a glasses case.
[0364] The glasses case and the applicator can be provided with Qi technology such that the battery of the applicator 1 is wirelessly chargeable. Furthermore, the glasses case itself can be provided with a battery such that the glasses case without cables can wirelessly charge the battery of the applicator 1 by using the battery of the glasses case.An alternative applicator 1 can be provided with two transparent spectacle glasses enclosed in a frame, wherein each spectacle glass is positioned in front of an eye of a person by a frame for positioning on the ears and the nose of said person, the applicator 1 further provided with at least one light source integrated in the frame, wherein above the spectacle glass the frame is provided with at least a light guiding element for indirect delivery of light (blue photons) substantially from above the spectacle glass to the eyes, the light originating from at least one light source. The alternative applicator 1 comprises a light guiding element with notches as herein described and as shown in the Figures. Optionally, the alternative applicator 1 may comprise a frame with light reflecting parts of the applicator 1 , such as the inner surface 39 of the support frame 9 located below the light guiding elements 25, 26, 50 and / or the lining, reflecting to the eye at least partially the direct or indirect incident light thereon originating from the light source, e.g. reflecting the incident light for at least 50%, preferably for more than 85%.
[0365] An alternative embodiment of the applicator is shown in Figures 15 and 16. Figure 15 shows a perspective front view of an applicator 1 configured as a wearable optical device for administering blue photons to the eyes of a human subject. Figure 16 shows a horizontal plane view from above of the applicator 1. The applicator 1 comprises a frame-like structure 5 that includes two legs, a first leg 7a and a second leg 7b, which extend from either side of the frame-like structure 5 and are designed to rest on the wearer's ears.
[0366] The frame-like structure 5 includes a support frame 9 with a support frame upper part 23 that extends horizontally across the upper portion of the applicator 1. The support frame upper part 23 is positioned to sit above the eyes of the wearer when the applicator 1 is worn correctly. At the center of the support frame upper part 23, a nose frame part 15 is connected, which is configured to rest on the nose of the human subject.
[0367] The frame-like structure 5 includes a frame side portion 12 on one side and a frame side portion 14 on the opposite side. These frame side portions 12, 14 connect the support frame upper part 23 to the respective legs 7a, 7b. The frame-like structure 5 forms two openings positioned in front of where the wearer's eyes would be located, allowing the wearer to see through the applicator 1.
[0368] Spectacle glass 3a and spectacle glass 3b are positioned within the openings of the frame-like structure 5, one in front of each eye of the wearer. These spectacle glasses 3a, 3b are transparent elements that allow vision while the applicator 1 is worn.
[0369] Integrated into the frame-like structure 5 are light sources for emitting blue photons. Light source L and light source L’ are positioned within the first leg 7a and a second leg 7b, respectively, which are optionally substantially positioned above the spectacle glasses 3a, 3b. These light sources L, L’ comprise the blue photon emitting composition and are configured to emit blue photons indirectly toward via the spectacle glasses 3a, 3b to the eyes of the wearer when the applicator 1 is worn on the nose and ears.
[0370] The overall construction of the applicator 1 provides a glasses-like appearance while incorporating light sources L, L’ in the first leg 7a and a second leg 7b, respectively, provides delivering blue photons to the retina of the wearer's eyes.The figure 16 shows a upper view of an applicator 1 of Figure 15. Figure 16 illustrates light paths showing the direction of blue photon delivery. Light path P1 and light path P2 indicate the initial directions of light emission from the light sources L and L'. Spectacle glass 3a and spectacle glass 3b are positioned within the openings of the frame-like structure 5, one in front of each eye of the wearer. These glasses 3a and 3b are configured for reflecting the light path P1 and light path P2 towards the eyes of the human subject. Reflected light path P3 and second reflected light path P4 show how the blue photons are redirected toward the eyes of the human subject, demonstrating the indirect delivery of blue photons to the retina of the wearer's eyes. The reflected light path P3 and second reflected light path P4 indicate the directions in which blue photons travel from the light sources L, L’ toward the eyes of the wearer, illustrating how the light is indirectly reflected by the spectacle glasses 3a, 3b to the eyes of the human subject. In specific examples, the glasses 3a and 3b are locally provided with a coating to predominantly reflect blue photon wavelengths to the eyes of the subject.
[0371] The positions the light sources L, L’ within the frame legs 7a and 7b and the direction of the light path P1 and light path P2 is determined based on the desired light path P3 and P4 towards the eyes of the wearer. The overall construction of the applicator 1 provides a glasses-like appearance while incorporating light sources L, L’ in the frame legs 7a, 7b provides an alternative positioning for delivering blue photons to the retina of the wearer's eyes.
[0372] Figure 17 and 18 show another embodiment of the applicator 1. Figure 17 shows a perspective front view of an applicator 1 configured as a wearable optical device for administering blue photons to the eyes of a human subject. Figure 18 shows a front view of the applicator 1. The applicator 1 comprises a frame-like structure 5 that includes two legs, a first leg 7a and a second leg 7b, which extend from either side of the frame-like structure 5 and are designed to rest on the wearer's ears.
[0373] The frame-like structure 5 includes a support frame upper part 23 that extends horizontally across the upper portion of the applicator 1. The support frame upper part 23 is positioned to sit above the eyes of the wearer when the applicator 1 is worn correctly. At the center of the support frame upper part 23, a nose frame part 15 is connected, which is capable to rest on the nose of the human subject.
[0374] The first leg 7a is connected to the frame-like structure 5 via a hinge 11 , while the second leg 7b is connected to the frame-like structure 5 via a hinge 19, allowing the legs to fold toward the support frame upper part 23 of the frame-like structure 5 for storage.
[0375] Integrated into the support frame upper part 23 are light sources for emitting blue photons. Light source L and light source L’ are positioned within the support frame upper part 23. These light sources L, L’ comprise the blue photon emitting composition and are configured to emit blue photons toward the eyes of the wearer when the applicator 1 is worn correctly.
[0376] The applicator 1 includes light guiding elements 72 that are integrated with the frame-like structure 5 and are positioned facing each eye respectively. The light guiding element 72 is positioned to guide and direct blue photons emitted from the light sources L, L’ toward the eyes of the human subject wearing the applicator 1.
[0377] The overall construction of the applicator 1 provides a glasses-like appearance while incorporating light sources L, L’ in the upper frame portion for delivering blue photons to the retina of thewearer's eyes. The positions the light sources L, L’ above the eyes to enable administration of blue photons substantially from above to the wearer's eyes.
[0378] The light guide elements 72 in specific embodiments are implemented as shown in Figures 12F and 12G and contain a front surface pointing to the front in the orientation of Figure 12F, and a back surface 71 pointing towards the eye of the human subject wearing the applicator. The front surface has a smaller surface area than the back surface 71 , and therewith the surface 70 connecting the front surface and the back surface of light guiding element 72 protruding backwardly in the orientation shown with the surface 70 pointing away from the eye of the wearer. Blue light emitted from light sources L, L’ (e.g. blue-photon emitting composition such as LED) in direction indicated with arrows L10, L11 , L12, L13 is bent into the direction of the lens of the eye of the human subject wearing the applicator, indicated by arrows L10’, L11 ’, L12’, L13’, here pointing backwardly. As a result, blue photons emitted by the bluephoton emitting composition comprised by light source L, L’ is provided to the retina of the eye of the human subject wearing the applicator from above the eye of the human subject and is provided indirectly from the light source to the retina. The surface 70 is provided with a structured surface to direct the light L10’, L11’, L12’, L13’ in a scattered way towards the respective eye of the human subject, or, alternatively, is provided with a surface structure to substantially direct all the light L10’, L11’, L12’, L13’ towards the respective eye of the human subject. The structured surface 70 may comprise a roughened surface configured to provide scattered light or may comprise a structure of notches, such notches 55 as shown in Fig. 12A - 12C. The scattered light has the advantage that independent of the position of the surface 70 with respect to the eye, at least some part of the light L10’, L11’, L12’, L13’ in a scattered way towards the respective eye of the human subject. At the same time also a part of the light is not directed to the respective eye of the human subject. Said applicator 1 may also be supported on top of other glasses, which is supported on the nose of the subject when worn by the subject, instead of supporting the applicator 1 directly on top of the nose of the subject. The nose frame part 15 may be provided flexible in order to be bended in any position depending on the size of the nose or to be deflected when supporting the applicator 1 on top of other glasses.
[0379] Alternatively to the application of blue light emitting LEDs, different light sources than such LEDs are also applicable in the applicator 1. For example, a photon source such as a blue-light fluorescent dopant comprised by an organic LED (OLED) light source or a photon source such as a deep-blue light phosphorescent dopant comprised by a phosphorescent organic LED (PHOLED) light source, wherein said photon source is capable of emitting blue light, is also applicable for application in the light sources comprised by the applicator 1. Such a photon source comprised by an OLED light source is for example a blue fluorescent dopant for example with an emission peak wavelength of about 468 nm, such as for example 3-(9H-[3,9'-bicarbazol]-9-yl)-9H-xanthen-9-one-dibenzo[b,d]furan-2,8-diylbis(diphenylphosphine oxide) (CCX-I:PPF). Such a photon source comprised by a PHOLED light source is for example a blue phosphorescent dopant for example with an emission peak wavelength of about 468 nm, such as for example an organometallic-iridium(lll) complex and benzo(e)pyrene. Of course, many more blue fluorescent dopants and blue phosphorescent dopants for application in blue light emitting OLED light sources and PHOLED light sources, respectively, are known in the art, and are equally applicable in a light source comprised by the applicator 1 , as long as the application of suchphoton sources in the applicator provide for an applicator capable of delivering at least about 125 M-EDI lux, preferably 200 - 300 M-EDI lux, at the level of the eye of the wearer of the applicator.
[0380] An aspect of the invention is therefore the applicator 1 comprising the blue photon emitting composition, for administration of photons to an eye of a human subject comprising
[0381] a. two legs 7a, 7b for positioning the applicator 1 on the ears of the human subject, b. a support frame 9 comprising a support frame upper part 23 which is positioned above the eyes of the human subject when the applicator 1 is worn correctly, and which extents in between frame legs 7a, 7b of the applicator 1 , wherein at its center, the support frame upper part 23 is connected with a nose frame part 15,
[0382] c. at least one light source 51 , 53, L, L’ comprising the blue photon emitting composition, the light source integrated in the upper part 23 of the support frame 9 of the applicator 1 , and
[0383] d. the nose part 15 connected to the center of the upper part 23 of the support frame 9 of the applicator 1 ,
[0384] wherein the applicator 1 is configured for direct and / or indirect administration of blue photons from above to the eyes of the human subject who wears the applicator 1 on the nose and on the ears (when the applicator 1 is worn correctly).
[0385] Preferably, the applicator 1 further comprises at least one light guiding element 25, 25’, 26, 26’, 50 integrated in the upper portion 23 of the support frame 9 of the applicator 1 above the eyes of the human subject wearing the applicator 1 , for direct and / or indirect administration of blue photons originating from the at least one light source 51 , 53, L, L’.
[0386] In a preferred embodiment, the at least one light guiding element 25, 25’, 26, 26’, 50 is integrated in the inner wall of the upper portion 23 of the support frame 9 of the applicator 1 and is configured to indirectly deliver the blue photons substantially from above the eyes of the human subject.
[0387] In a preferred embodiment, the at least one light guiding element 25, 25’, 26, 26’, 50 is reflective, and optionally the at least one light guiding element 25, 25’, 26, 26’, 50 comprises a whitening agent.
[0388] Preferred is the embodiment, wherein at least one light source 51 , 53, L, L’ is positioned at one end 27, 29 of the at least one light guiding element 25, 25’, 26, 26’, 50, preferably at least one light source 51 , 53, L,L’ is positioned at both ends 27, 29 of each of light guiding element 25, 25’, 26, 26’, 50.
[0389] In a preferred embodiment, the at least one light guiding element 25, 26, 50 comprises at the bottom side 61 a protrusion 59 extended below facing towards the eye of the human subject, when wearing the applicator 1 , or wherein the at least one light guiding element 25’, 26’ comprises at the bottom side 70 a protrusion extended below facing away from the eye of the human subject, when wearing the applicator 1.
[0390] Preferably, the protrusion 59 is positioned towards the eye of the human subject at an angle a with respect to the surface of the at least one light guiding element 25, 26, 50, wherein the angle a ranges from 0° to 70° or 15° - 50°, wherein the protrusion at the bottom side 70 is positioned away from the eye of the human subject at an angle a with respect to the surface of the at least one light guiding element 25’, 26’, wherein the angle a ranges from 0° to 70° or 15° - 50°.Preferably, the at least one light guiding element 25, 25’, 26, 26’, 50 further comprises notches 55 extending along at least a part of the upper side 57 thereof in between two flat-portions of the upper side 57.
[0391] Preferably, said notches 55 are of triangular cross-section where each notch has a center 63 which are equally distant from each other.
[0392] In a preferred embodiment, the depth of the center 63 of notches are increasing towards the at least one end of the notches 55, preferably the depth of the center 63 of notches are increasing towards the end positioned next to the legs 7a, 7b of the applicator 1.
[0393] Preferably, the applicator 1 comprises a frame-like structure 5 which forms an opening 3a’, 3b’ below the upper portion 23 of support frame 9 and encloses only partially the perimeter of said opening(s) 3a’, 3b’ positioned in front of the eyes of the human subject when wearing the applicator 1 .
[0394] Preferably, the frame-like structure 5 has inner side-walls 16, 38 located below the at least one light guiding element 25, 25’, 26, 26’, 50 and said inner side-walls 16, 38 are reflective.
[0395] More preferably, the applicator 1 comprises a lower portion 39 connected to the frame-like structure 5 and upper portion 23 of the support frame 9 of the applicator 1 wherein said lower portion entirely encloses the opening(s) 3a’, 3b’ positioned in front of the eyes of the human subject when wearing the applicator.
[0396] In a preferred embodiment, the lower portion 39 comprises a reflective surface which reflects the blue photons emitted from the blue light emitting composition and / or reflected from elsewhere, to the eye of the human subject when wearing the applicator, optionally said lower portion 39 comprises a whitening agent.
[0397] Preferably, the reflective surface of the inner side-wall 38 and / or the lower portion 39 is positioned towards the eye of the human subject when wearing the applicator 1 , at an angle B with respect to the horizontal-axis, wherein the angle B ranges from 0° to 70° or 15° - 50°.
[0398] Preferred is the applicator 1 , wherein the frame-like structure 5 has sides 35, 36 facing the human subject when wearing the applicator 1 , and inner surface 38 lining the opening(s) 3a’, 3b’; said sides 35, 36 and inner surface 38 being reflective.
[0399] Preferably, the applicator 1 is configured for direct and / or indirect administration of blue photons from above to the retina of the eyes of the human subject wearing the applicator 1.
[0400] Preferably, the applicator 1 is configured for direct and / or indirect administration of blue photons to the parafoveal area of the retina and / or the perifoveal area of the retina and / or the optic disc (‘blind spot’) of the eye of the human subject when wearing the applicator 1.
[0401] Preferably, is the applicator 1 , comprising the blue photon emitting composition, wherein the photon energy of the blue photons emitted by the composition is selected from the range 3,10 eV - 2,48 eV, or wherein the wavelength of the blue photons emitted by the composition is selected from the range 400 - 500 nm, or 440 - 490 nm, or 450 - 482 nm, or 460 - 480 nm, or 464 - 480 nm, or, 468 - 480 nm.
[0402] Preferably, the blue photon emitting composition emits blue photons with a M-EDI of 100 - 500 lux, or 150 - 400 lux, or 200 - 250 lux.
[0403] It is preferred that the blue photon emitting composition is a LED selected from a semi-conductor composition selected from any of:gallium nitride (GaN);
[0404] wide-gap ll-VI semiconductor such as zinc selenide (ZnSe);
[0405] indium-gallium nitride (InGaN); and
[0406] p / n semiconductor composition consisting of a p-layer and an n-layer, wherein the p-layer and the n-layer are both InGaN.
[0407] Preferably, the blue photon emitting composition is a LED that is a wide band-gap semi-conductor composition of the direct transition type with an energy band gap of 2.6 eV or larger.
[0408] DELIVERY OF BLUE PHOTONS TO THE RETINA
[0409] Without wishing to be bound by any theory, melanopsin on the surface of ipRGC is sensitive and activatable by blue photons. Blue photons relate to blue light with a wavelength of about 400 - 500 nm, or 400 - 510 nm. Melanopsin is said to have optimal sensitivity for blue photons around 472 nm. Therefore, preferred is the embodiment, wherein the photon energy of the blue photons emitted by the blue-light emitting composition (blue photon emitting composition) is selected from the range 3,10 eV -2,48 eV, or wherein the wavelength of the blue photons emitted by the composition is selected from the range 400 - 500 nm, or 440 - 490 nm, or 450 - 482 nm, or 460 - 480 nm, or 464 - 480 nm, or, 468 -480 nm. Preferably, the blue light emitted by the blue-photon emitting composition is 440 - 490 nm, or 450 - 485 nm, preferably 460 - 482 nm, such as about 462, 463, 464, 465, 466, 467, 468, 469, 470, 471 , 472, 473, 474, 475, 475, 476, 477, 478, 479, 480, 481 , 482 nm, more preferably about 464 nm, 468 nm, 472 nm, 476 nm, 480 nm or 484 nm, even more preferably ± 2 nm or ± 1 nm. In preferred embodiments, the wavelength is 468 nm.
[0410] For example, the LEDs for emitting the blue light may be provided with filters for filtering the eye-damaging part of the light spectrum of the light emitted by the light source, such as, for example, UV radiation having a wavelength between 10 and less than 400 nanometer. These filters can also be provided elsewhere in the applicator to prevent a malicious part of the light emitted with the light source (i.e. the blue-photon emitting composition such as the LED) from reaching the eye. Preferably, the LEDs for emitting blue light do not emit UV light. This way, exposing the retina of the eyes of the human subject to whom the blue-photon emitting composition is administered, to harmful UV light emitted by the composition is prevented. Preferably, the blue light emitted by the composition such as LEDs has a wavelength of between 460 nm and 480 nm, + / - 10 nm. More preferably, the blue light emitted by the composition such as LEDs has a wavelength of about 470 nm + / - 10 nm. Preferably, two to four light sources comprising the blue-photon emitting composition such as a LED are provided, wherein said composition, e.g. LEDs for emission of blue light, has an emission peak wavelength of a wavelength selected from 460 - 485 nm, preferably a wavelength of about 468 nm, and a spectral line half width of about 25 nm. It is preferred that said blue-photon emitting composition, for example LEDs, are provided as one to four light sources such as 1 , 2, 3 or 4 light sources, wherein the light source (photon source) is capable of delivering at least 100 M-EDI lux, for example 120 - 800 M-EDI lux, preferably at least 150, 200, 225, 250, 275, 300, 325, 350, 400, 450, 500, 550, 600, 700 M-EDI lux, or any value thereinbetween, at the level of the eye of the human subject to whom a dose of blue photons is administered by administering the blue-photon emitting composition, or at the level of the retina of the human subject. Preferably, the light sources comprises a LED as the blue-photon emitting composition, wherein said composition is a p / n semiconductor material consisting of a p-layer and an n-layer of InGaN (e.g. product LTST-108TBKT; Lite-on Technology Corporation). In the Table, below, further examples of applicable LEDs, i.e. blue-photon emitting compositions, are listed. A blue light emitting LED with an emission peak wavelength of about 468 nm and a relatively small full width at half maximum spectral band width of about 18 nm to 37 nm, preferably about 24 nm, is preferred.
[0411] TABLE: LEDs applicable as a composition for administration of blue photons
[0412] Emission peak wavelength X.0,5, the Full Width at Half
[0413] LED (supplier) (nm) Maximum spectral bandwidth (nm) ASMT-AL31
[0414] 450.0 19.5
[0415] (Broadcom - Avago)
[0416] ASMT-JL-31-NPQ01
[0417] 452.6 24.0
[0418] (Broadcom - Avago)
[0419] 21 .00.01 B (XLED, Italy) 454.7 28.0
[0420] ASMT-JL11-NM
[0421] 456.5 25.7
[0422] (Broadcom - Avago)
[0423] ASMT-JB-31-NMP01
[0424] 459.9 24.0
[0425] (Broadcom - Avago)
[0426] LB-W5SN-GYHZ-25 (Osram
[0427] 460.0 32.6
[0428] opto semiconductors)
[0429] LB-T673-L2P1-35
[0430] (Osram opto 462.2 20.0
[0431] semiconductors)
[0432] LT-T67C-K1M2-35 465.0 n.d.
[0433] VAOL-S2SB4 with source 468 (minimum dominant X is
[0434] color InGaN 464,0 nm, maximum 35
[0435] (VCC optoelectronics) dominant X is 472,0 nm)
[0436] LTST-C194TBKT with 468 (minimum dominant X is
[0437] source color InGaN 460,0 nm, maximum 25
[0438] (Lite-on technology corp.) dominant X is 475,0 nm)
[0439] LV-W5AM-JYKY-25 (Osram
[0440] 501.7 28.0
[0441] opto semiconductors)
[0442]
[0443] Without wishing to be bound by any theory, optimal synchronization of the circadian rhythm with the environmental conditions is achieved if a human subject is exposed to day light equivalent to about250 M-EDI lux that enters the eye from the vertical direction. That is to say, exposing a human subject to an artificial light source emitting blue photons to the eye from the vertical direction would be most effective in synchronizing the circadian rhythm when applied at 250 M-EDI lux. The inventor now achieved beneficial improvements relating to treating disturbed circadian rhythm when human subjects, such as PD patients, were subjected to blue-photon emitting composition emitting blue photons with 125 M-EDI lux or 250 M-EDI lux. The blue photons were directed to the eye of the human subjects substantially from above. Preferred is the embodiment, wherein the blue photon emitting composition emits blue photons with a M-EDI of 100 - 500 lux, or 150 - 400 lux, or 200 - 250 lux.
[0444] Since ipRGC comprising the melanopsin that is sensitive to illumination with blue photons are sparsely present in the retina (about 2% or less of all ganglion cells present in the retina), and since in for example PD patients, ipRGC function or number is often declined, it is beneficial to illuminate as many ipRGC as possible by administering the blue-photon emitting composition and therewith administering the blue photons. Therefore, the embodiment is preferred, wherein the blue photon emitting composition emits blue photons at least in the direction of the retina of the human subject, or the parafoveal area of the retina and / or the perifoveal area of the retina and / or the optic disc (‘blind spot’) of the eye and / or the nasal quadrant of the retina and / or the nasal ventral posterior section of the retina, or in the direction of any combination thereof. The highest density of ipRGC in the human retina is identified in the parafoveal area of the retina, the perifoveal area of the retina and the optic disc (‘blind spot’) of the eye. Without wishing to be bound by any theory, it is also assumed that a higher density of melanopsin bearing cells is apparent in the ventral-nasal-posterior surface area of the human retina. Therefore, the inventor established that it is beneficial to minimally directed blue photons to these areas of the retina surface.
[0445] Preferred is the embodiment, wherein the blue photon emitting composition emits blue photons to at least 60% of the surface area of the retina, orto at least 70%, 80%, 90%, 95%, 95%, 98%, 99% or to 100% of the surface area of the retina. By application of the applicator 1 , administration of the bluephoton emitting composition and therewith the administration of the blue photons is efficiently established at, at least 60% of the retina surface area, wherein at least the parafoveal area of the retina, the perifoveal area of the retina and the optic disc (‘blind spot’) of the eye are exposed to the blue photons and therewith the large fraction of the melanopsin bearing ipRGC present in the retina.
[0446] Preferably, the applicator 1 is configured for direct and / or indirect administration of blue photons to the parafoveal area of the retina and / or the perifoveal area of the retina and / or the optic disc (‘blind spot’) of the eye of the human subject when wearing the applicator 1.
[0447] An aspect of the invention relates to the applicator 1 for use in a method of administration of blue photons to an eye in a human subject, wherein the method comprises wearing of the applicator 1 by the human subject twice daily for a total of two hours, preferably the applicator 1 is used one time in the morning, more preferably after awaking the in the morning, even more preferably within 0 - 60 minutes after awaking.
[0448] In an embodiment, the method further comprises at maximum a single daytime sleeping period of the human subject in between the twice daily administration. Preferably, the method comprises no sleeping period during day time at all.Preferably, the applicator 1 is configured to directly and / or indirectly administer blue photons to an eye of the human subject for stimulating melanopsin on a ipRGC to ease human subject’s sleep disorder conditions due to Parkinson’s disease.
[0449] In a preferred embodiment, the applicator 1 is for use in a method of stimulating melanopsin on an ipRGC in the retina of a human subject wearing the applicator 1 , wherein the method comprises wearing of the applicator 1 by the human subject twice daily for a total of two hours, preferably the applicator is used one time in the morning and one time in the evening.
[0450] Preferably, for said use, the applicator 1 is worn by the human subject in the morning preferably after awaking in the morning, even more preferably within 0 - 60 minutes after awaking, and wherein the applicator 1 is worn by the human subject in the evening preferably about 11 hours after the end of the first use in the morning, more preferably in addition no later than starting 2 hours before the night sleep period of the human subject wearing the applicator 1 starts.
[0451] An aspect of the invention relates to a dose of blue photons (400 - 500 nm, preferably 440 -490 nm, more preferably 450 - 482 nm, even more preferably, 460 - 480 nm, even more preferably 464 - 480 nm, even more preferably, 468 - 480 nm) for use in a method of treating sleep disorder in a human subject suffering from PD, wherein the method comprises the twice daily administration of a dose of blue photons to the eyes of the human subject wherein a dose of blue photons is the amount of blue photons administered directly and / or indirectly by the applicator 1 within 0 - 60 minutes to an eye of the human subject wearing the applicator.
[0452] This aspect of the invention hinges on the particle like traits of photons, with which traits photons can be defined as a substance. By the application of a blue-photon emitting composition such as a LED, a dose of particle-like photons can be administered to the retina of the eye of a human subject, for example by application of the applicator 1 when worn correctly by the human subject. The photons (substance) is then contacting the melanopsin expressed on the surface of the ipRGC in the retina, therewith triggering the activation of the ipRGC as herein above outlined.
[0453] Preferred is the embodiment, wherein the twice daily administration comprises: administration of a first dose of blue photons after awaking in the morning, preferably within 0 - 60 minutes after awaking;
[0454] the first dose of blue photons being emitted for about 45 minutes to 60 minutes of administration at a M-EDI of 100 - 500 lux, preferably 150 - 400 lux, more preferably 200 - 250 lux;
[0455] a daytime sleeping period which involves sleeping for 0- 20 minutes in between the period from noon till 2 pm;
[0456] administration of a second dose of blue photons at least 11 hours after the end of the administration of the first dose, wherein the second administration starts no later than 2 hours before the start of the nighttime sleep period of the human subject wearing the applicator 1 ; the second dose of blue photons being emitted for about 45 minutes to 60 minutes of administration at a M-EDI of 100 - 500 lux, preferably 150 - 400 lux, more preferably 200 - 250 lux.In preferred embodiments, relating to the applicator 1 for use in the method or relating to the dose of blue photons, the human subject is a patient with PD suffering from sleep disorder.
[0457] In preferred embodiments, relating to the applicator 1 for use in the method or relating to the dose of blue photons, the human subject is a sleeping disorder patient and / or a patient with a disturbed circadian rhythm, preferably a patient suffering from a sleeping disorder and / or a disturbed circadian rhythm due to a jet lag (time zone travelling) and / or nightshift work.
[0458] KIT OF PARTS
[0459] An aspect of the invention is a kit of parts comprising the blue photon emitting composition and comprising a leaflet with instructions for administering blue photons to the retina of the eye(s) of the human subject, for example by wearing an applicator such as any of the applicators as detailed below and in the drawings Figures 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17 and 18, preferably the applicator 1 , and therewith administration of the blue photon emitting composition in the proximity of the eye of the human subject, or with instructions for administration of a therapeutically effective amount of blue photons emitted by the blue photon emitting composition to the retina of the eye(s) of the human subject by administration of the blue photon emitting composition in the proximity of the eye of the human subject for the treatment of the non-motor symptoms in the human subject, for example by wearing an applicator such as any of the applicators as detailed below and in the drawings Figures 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17 and 18, preferably the applicator 1 , on the nose and ears of the human subject.
[0460] An aspect of the invention relates to a kit of parts comprising the blue photon emitting composition as hereabove outlined, or the applicator 1 , and a leaflet with instructions for administering blue photons to the retina of the human subject by wearing the applicator 1.
[0461] The leaflet can outline that by wearing the applicator, blue photons are administered to the ipRGC in the retina of the eye(s) of the human subject. Therefore, an embodiment is the kit of parts, comprising instructions for administering blue photons to the retina of the human subject by wearing the applicator 1 (on the nose and ears of the human subject) and therewith administration of the blue photon emitting composition in the proximity of the eye of the human subject, or with instructions for administration of a therapeutically effective amount of blue photons emitted by the blue photon emitting composition to the retina of the eye(s) of the human subject by administration of the blue photon emitting composition in the proximity of the eye of the human subject by wearing the applicator 1 on the nose and ears of the human subject, for the treatment of the non-motor symptoms such as depression, sleep disturbance, disturbed circadian rhythm, fatigue, such as in a human subject suffering from a neurodegenerative disease such as PD, or suffering from the non-motor symptoms due to a jetlag or working in nightshift.
[0462] BRIEF SUMMARYA preferred embodiment is the blue photon emitting composition for use in the treatment of non-motor symptoms, the method for treatment of a human subject, or the use for the manufacture of a blue-photon emitting composition, or the kit, as hereabove outlined and as claimed, wherein:
[0463] (i) the blue photons are administered to the ipRGC in the retina of the human subject substantially from above the eye(s) of the human subject; and / or
[0464] (ii) the blue photons are administered to the eye(s) of the human subject indirectly by the administered blue photon emitting composition; and / or
[0465] (iii) the blue photon emitting composition is administered to the eye(s) of the human subject by positioning the blue photon emitting composition in the proximity of the eye(s) of the human subject by wearing the applicator 1 on the nose and ears of the human subject; and / or (iv) the light emitted by the blue photon emitting composition has a wavelength of 460 - 480 nm; and / or
[0466] (v) two daily doses of blue photons are administered to the human subject; and / or
[0467] (vi) the first dose of blue photons administered during a day is administered to the human subject after awaking of the human subject in the morning, preferably within 0 - 60 minutes after awakening; and / or
[0468] (vii) the second dose of blue photons is administered to the human subject at least 11 hours after administration of a first dose of blue photons, or 11-15 hours after administration of a first dose of blue photons; and / or
[0469] (viii) the start of the dosing of the second administered dose of blue photons is no later than 2 hours before bedtime of the human subject; and / or
[0470] (ix) the blue photons are dosed by administering the first dose and the second dose each to the retina of the eye(s) of the human subject by emission of blue photons by the blue photon emitting composition for a duration of 20 minutes - 90 minutes; and / or
[0471] (x) the human subject sleeps during daytime after awakening in the morning for at most one time for 30 minutes or less; and / or
[0472] (xi) the human subject sleeps during daytime after awakening in the morning for at most one time between noon and 2 p.m.; or
[0473] any combination of (i) - (xi), or all of (i) - (xi).
[0474] EXAMPLES & EMBODIMENTS - patient data after subjecting to blue-photon dosage regimen
[0475] Study in patients with PD suffering from sleep disorders
[0476] A randomized controlled single blinded second phase clinical study is conducted with 30 PD patients having sleep disorders divided randomly in a group of 15 patients receiving treatment and 15 patients receiving placebo. The patients have used the applicator 1 / glasses as herein described for Fig. 7, Fig.12A-D, and the blue-light photons have been administered to the patients according to a dosage regimen.
[0477] With that purpose adults and elderly (65 years and older) who are at the age of 30 and above are included in the study.
[0478] A human subject is considered to be a PD patient if he / she has been diagnosed with idiopathic PD according to UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria with Hoehn & Yahr stage 2-4.
[0479] The status of the sleep disorder of the PD patients was assessed based on the Pittsburg Sleep Quality Index Score (PSQI) and established by determining excessive daytime sleepiness (EDS) defined by the Epworth Sleepiness Scale (ESS).
[0480] The PD patients participating in the study had a PSQI score of 5 or more or had an ESS score of 7 or more, and therewith were considered as PD patients having sleep disorder.
[0481] PD patients were on anti-PD treatment, for example, receiving levodopa formulations, dopamine agonists, selective monoamine oxidase type B (MAO-B) inhibitors, anticholinergic agents or amantadine at a stable dose in the last 30 days prior to the initial screening assessment.
[0482] PD patients that have participated in the study did not have Atypical Parkinsonism and / or clinically significant psychiatric illness and do not suffer from other conditions associated with sleep disorders other than PD, or conditions inferring with the delivery of the blue light treatment including obstructive sleep apnoea syndrome, eye-related diseases, and the patients did not have current or history of malignancy or migraine within 5 years before screening. Participating patients were not on current use, or did not use within three months prior the initial screening, of hypnosedative or stimulant drugs such as benzodiazepines or melatonin.
[0483] The study was a placebo controlled single-blind study in which all the participants were randomly allocated for the administration of (1) either blue-light photons at a wavelength of 468 nm with the applicator 1 I glasses as hereabove described as the intervention group; (2) or red light photon therapy as the placebo group, by application of the same applicator 1 , now equipped with orange-red spectacle glasses, without provision of blue photons.
[0484] The intervention group received the blue light photons for one hour twice daily (total two hours each day). During the first daily session the participants wore the applicator for one hour after the PD patients woke up in the morning and during the second session the PD patients wore the applicator for one hour starting at least three hours before preferred bed time.
[0485] Control group:
[0486] Placebo consisted of red light therapy being administered using the same applicator design as the blue photon therapy but with red spectacle glasses 3a, 3b in the openings 3a’, 3b’ of applicator 1. The red light protocol was identical to the blue light protocol, thus also requiring the trial participants to wear the applicator twice daily for one hour (total two hours each day). Each participant was using the blue light therapy for a total of two weeks or the red light therapy for two weeks as well.
[0487] ResultsLight therapy was well tolerated for all PD patients included in the trial. The rate of adverse events was around 6%. Reported side effects include mild headache, sleepiness and itchy eyes. These adverse effects all resolved spontaneously after secession of the intervention. The same amount and nature of side effects have been reported in the red light placebo therapy arm of the trial.
[0488] In terms of benefit, the participants receiving the blue light therapy showed significant improvements in e.g. reduction of daytime sleepiness, improvement of sleep quality and self-reported subjective sleep metrics, such as sleep fragmentation, sleep quality, ease of falling asleep. In addition, the PD patients in the blue-photon therapy arm reported improvement of depressive mood and in addition also showed improved motor scores, reflected by better scores on the Unified Parkinson's Disease Rating Scale (UPDRS).
[0489] The sophisticated dosage regimen of blue-light photons emitted from a blue-light photon source by a semiconductor composition, was effective in providing almost complete relief from sleep disturbance related symptoms in the PD patients receiving the blue photons. In addition, the PD patients were also relieved to a beneficial extent from motor symptoms of PD, such as bradykinesia, muscle stiffness, muscle rigidity, hypomimia (facial mask) and tremor. PD patients were very successfully subjected to a dosage regimen comprising administering twice daily a dose of blue-light photons relating to time and Melanopic Equivalent Daylight Illuminance ( M-EDI) at standardized moments during daytime, targeted delivered evenly to the sparsely present ipRGC in the eye’s retina of the PD patients, in combination with a very limited and restricted daytime sleep regimen both in moment at the time of day and in length, i.e. at most once daily sleep (also referred to as a power nap) for at most 20 minutes within the daytime period of noon till 2 pm. Patients subjected to the blue-light photons dosage regimen in combination with the stringent limited-access-to-daytime-sleep therapy experienced an overall surprisingly high improvement of their quality of life, both during night and during daytime. That is to say, subjecting PD patients to the new therapy including twice daily the activation of the photopigment melanopsin expressed on the surface of the ipRGC in the retina of the patient’s eye by contacting melanopsin on the ipRGC cell surface with the blue-light, resulted in improved sleep quality during the night, even with fully undisturbed sleep for a large number of patients, and reduced sleepiness and tiredness during the day. In addition, initially present symptoms of depression before start of therapy disappeared almost completely for the PD patients upon adhering to the newly developed PD blue-light photon therapy with almost complete daytime sleep deprivation (at maximum once daily for at maximum 20 minutes between noon and 2 pm). PD patients suffering from depression, mood swings, sleepiness during daytime, bad sleep quality during night time, reported close to none side effects relating to the new therapy (only some mild effects were reported), whereas they reported a surprisingly high improvement of the primary outcome of the conducted randomized placebo-controlled clinical trial, i.e. an increase in PSQI score compared to the pre-treatment period, up to an effect size expressed as Pearson correlation coefficient (r; with a value running between 0 and 1) with value of 0,896, with a much lower score for the placebo group. The effect size for sleepiness was even as high as 0.918, again with a much lower score for the placebo group, and for relief from depression the effect size was 0,556 (placebo control group: effect size of 0,088), due to subjecting the PD patients to the new blue photon I daytime sleep deprivation therapy.The PD patients were subjected to a twice daily blue-light photons administration regimen: a first dosage of blue-light photons was administered directly after awaking in the morning, that is to say, within 0 - 60 minutes after awaking. The administered dose, as applied by the PD patients themselves, ranged from 45 minutes to 60 minutes administration of blue-light photons emitted at a M-EDI of 125 lux. PD patients were allowed to sleep once for at most 20 minutes during daytime, in between the period from noon till 2 pm. A second dosage of blue-light photons (the last dose of photons administered to a patient since awakening in the morning) was administered after at least 11 hours had lapsed after the end of the first dosage administration and the period in which said second dosage was administered was in any occasion started no later than 2 hours before the start of the nighttime sleep period of the patient (‘bedtime”) (the moment at which the human subject goes to bed and lays down for a resting period of sleeping, typically during nighttime, and here preferably during nighttime). The selfadministered dose by the PD patients was again 45 minutes to 60 minutes administration of blue-light photons emitted at a M-EDI of 125 lux in the double-blind randomized placebo-controlled clinical trial. For example, if a PD patient starts his / her night sleep at 11 pm, the second administration of the bluelight photons ended no later than at 9 pm. This way, the two doses separated at least 11 hours apart mimic a regular daytime with regular exposure to daylight. Melatonin production during daytime is effectively suppressed upon conducting the blue-photon therapy with limited sleep period during daytime (at most one period of at most 20 minutes within the fixed and defined moment of the day), with the strong result of absence of sleepiness, tiredness and depression for virtually all patients in the bluephoton arm of the clinical trial. The peak wavelength of the emitted blue-light photons applied was 468 nm. Moreover, the treatment regimen also allowed for a sleeping time during the night of at least 8 hours. The applied semi-conductor composition, comprised by the applicator, and capable of emitting the blue photons with the desired photon energy corresponding to blue light, was a LED consisting of a p / n semiconductor composition consisting of a p-layer and an n-layer, wherein the p-layer and the n-layer are indium-gallium nitride (InGaN).
[0490] REFERENCES
[0491] Hannibal, J., et al., “Melanopsin expressing human retinal ganglion cells: Subtypes, distribution, and intraretinal connectivity.”, J. Comp. Neurol. ;525:1934-1961 (2017). DOI 10.1002 / cne.24181
[0492] La Morgia, C., et al., “Retinal Ganglion Cells and Circadian Rhythms in Alzheimer’s Disease, Parkinson’s Disease, and Beyond.”, Front. Neurol. 8:162 (2017). doi: 10.3389 / fneur.2017.00162
[0493] Mure, L.S., et al., “Functional diversity of human intrinsically photosensitive retinal ganglion cells.”, Science. 2019 December 06; 366(6470): 1251-1255. doi:10.1126 / science.aaz0898.Ortuno-Lizaran, L., et al., “Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s disease.”, Acta Neuropathologica Communications (2018) 6:90. https: / / doi.org / 10.1186 / s40478-018-0596-z
[0494] Poewe, W. et al., “Parkinson disease.” Nat Rev Dis Primers 3, 17013 (2017). doi.org / 10.1038 / nrdp.2017.13
[0495] Steiner, O.L. & de Zeeuw, J., “Melanopsin retinal ganglion cell function in Alzheimer’s vs. Parkinson’s disease an exploratory meta-analysis and review of pupillometry protocols”, Parkinsonism and Related Disorders, 123, 106063, pp.1-9 (2024). doi.org / 10.1016 / j.parkreldis.2O24.106063
Claims
CLAIMS1. A blue photon emitting composition for use in the treatment of a human subject suffering from any one or more of non-motor symptoms:circadian rhythm disturbance;sleep disturbance during nighttime;sleepiness during daytime;tiredness during daytime;fatigue during daytime;depressed mood or depression;any combination of two - seven of these non-motor symptoms.
2. The blue photon emitting composition for use according to claim 1 , wherein the human subject (1) has a jet lag due to time zone travelling;(2) has worked during nighttime or is working during nighttime;(3) is a neurodegenerative disorder patient;(4) is a Parkinson’s Disease (PD) patient; or(5) has / is any combination of (1) - (4).
3. The blue photon emitting composition for use according to claim 1 or 2, wherein at least one dose of blue photons is administered to ipRGC in the retina of the eye(s) of the human subject by emission of blue photons by the blue photon emitting composition.
4. The blue photon emitting composition for use according to claim 3, wherein the dose of blue photons is administered twice daily to the human subject.
5. The blue photon emitting composition for use according to claim 3 or 4, wherein a second dose of blue photons is administered to the human subject at least 11 hours after administration of a first dose of blue photons, or 11-15 hours after administration of a first dose of blue photons.
6. The blue photon emitting composition for use according to any one of the claims 3-5, wherein the last dose of blue photons administered during a day is administered starting no later than 2 hours before bedtime of the human subject.
7. The blue photon emitting composition for use according to any one of the claims 3-6, wherein the first dose of blue photons administered during a day is administered to the human subject after awaking of the human subject in the morning, preferably within 0 - 60 minutes after awakening, or within 50, 45, 40, 35, 30, 25, 20, 15, 10, 5, 2, 1 minutes after awakening, or any time in between.
8. The blue photon emitting composition for use according to any one of the claims 3-7, wherein the blue photons are dosed by administering at least the first dose by emission of blue photonsby the blue photon emitting composition for a duration of 5 minutes - 2 hours, or 20 minutes - 90 minutes, or 30 minutes - 75 minutes, or 45 minutes - 60 minutes, or any time therein between or 100, 80, 70, 50, 40, 35, 25, 15 or 10 minutes, and / or by administering at least the second dose by emission of blue photons by the blue photon emitting composition for a duration of 5 minutes - 2 hours, or 20 minutes - 90 minutes, or 30 minutes - 75 minutes, or 45 minutes - 60 minutes, or any time therein between or 100, 80, 70, 50, 40, 35, 25, 15 or 10 minutes, or by administering the first dose and the second dose by emission of blue photons by the blue photon emitting composition for a duration of 5 minutes - 2 hours, or 20 minutes - 90 minutes, or 30 minutes - 75 minutes, or 45 minutes - 60 minutes, or any time therein between or 100, 80, 70, 50, 40, 35, 25, 15 or 10 minutes.
9. The blue photon emitting composition for use according to any one of the claims 3-8, wherein the human subject sleeps during daytime after awakening in the morning for at most one time for 0 minutes - 60 minutes, or 10 minutes - 45 minutes, or 20 minutes - 30 minutes, or 0 - 20 minutes.
10. The blue photon emitting composition for use according to claim 9, wherein the human subject sleeps during daytime after awakening in the morning for at most one time between 11 a.m. and 3 p.m., or between noon and 2 p.m.
11. The blue photon emitting composition for use according to any one of the claims 1-10, wherein the treatment lasts for at least 2, 3, 4, 5, 6 days, or at least 1 week, at least 2 weeks, at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 weeks, or any period therein between, or at least 4, 5, 6, 7, 8, 9, 10, 11 months, or at least 1 , 2, 3, 4, 5 years, or for the rest of the life time of the human subject.
12. The blue photon emitting composition for use according to claim 11 , wherein the treatment is provided as repeating cycles of a first cycle comprising a first treatment period followed by a first interval period without treatment of at least 2, 3, 4, 5, 6 days, or at least 1 week, at least 2 weeks, at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 weeks, or any period therein between, followed by at least a second cycle comprising a second treatment period and a subsequent second interval period.
13. The blue photon emitting composition for use according to any one of the claims 1-12, wherein the photon energy of the blue photons emitted by the composition is selected from the range 3,10 eV - 2,48 eV, or wherein the wavelength of the blue photons emitted by the composition is selected from the range 400 - 500 nm, or 440 - 490 nm, or 450 - 482 nm, or 460 - 480 nm, or 464 - 480 nm, or, 468 - 480 nm.
14. The blue photon emitting composition for use according to any one of the claims 1-13, wherein the blue photon emitting composition emits blue photons with a M-EDI of 100 - 500 lux, or 150 - 400 lux, or 200 - 250 lux.
15. The blue photon emitting composition for use according to any one of the claims 1-14, wherein the blue photon emitting composition is a light emitting diode (LED) selected from an inorganic LED or an organic LED (oLED), the inorganic LED selecting from a semi-conductor composition selected from any of:gallium nitride (GaN);wide-gap ll-VI semiconductor such as zinc selenide (ZnSe);indium-gallium nitride (InGaN); andp / n semiconductor composition consisting of a p-layer and an n-layer, wherein the p-layer and the n-layer are both InGaN,the organic LED selected from any of:9,10-bis (2-naphthyl )-2-t-butyl anthracene (TBADN);9,10-bis (2-naphthyl) anthracene (ADN);diaryl anthracene;di(styryl)arylene;fluorene; andpyrene.
16. The blue photon emitting composition for use according to any one of the claims 1-15, wherein the blue photon emitting composition is a LED that is a wide band-gap semi-conductor composition of the direct transition type with an energy band gap of 2.6 eV or larger.
17. The blue photon emitting composition for use according to any one of the claims 1-16, wherein the blue photon emitting composition emits blue photons at least in the direction of the retina of the human subject, or the parafoveal area of the retina and / or the perifoveal area of the retina and / or the optic disc (‘blind spot’) of the eye and / or the nasal quadrant of the retina and / or the nasal ventral posterior section of the retina, or in the direction of any combination thereof.
18. The blue photon emitting composition for use according to any one of the claims 1-17, wherein the blue photon emitting composition emits blue photons to at least 60% of the surface area of the retina, or to at least 70%, 80%, 90%, 95%, 95%, 98%, 99% or to 100% of the surface area of the retina.
19. An applicator (1) comprising a blue photon emitting composition, for administration of photons to an eye of a human subject comprisinga. two legs (7a, 7b) for positioning the applicator (1) on the ears of the human subject, b. a support frame (9) comprising a support frame upper part (23) which is positioned above the eyes of the human subject when the applicator (1) is worn correctly, and which extents in between frame legs (7a, 7b) of the applicator (1), wherein at its center, the support frame upper part (23) is connected with a nose frame part (15),c. at least one light source (51 , 53, L, L’) comprising the blue photon emitting composition, the light source integrated in the upper part (23) of the support frame (9) of the applicator (1), andd. the nose part (15) connected to the center of the upper part (23) of the support frame (9) of the applicator (1),wherein the applicator (1) is configured for direct and / or indirect administration of blue photons to the eyes of the human subject who wears the applicator (1) on the nose and on the ears, wherein preferably the administration of blue photons is from above to the eyes of the human subject who wears the applicator (1) on the nose and on the ears.
20. The applicator (1) according to claim 19, wherein the applicator (1) further comprises at least one light guiding element (25, 25’, 26, 26’, 50) integrated in the upper portion (23) of the support frame (9) of the applicator (1) above the eyes of the human subject wearing the applicator (1), for direct and / or indirect administration of blue photons originating from the at least one light source (51 , 53, L, L’).
21. The applicator (1) according to claim 19 or 20, wherein the at least one light guiding element (25, 25’, 26, 26’, 50) is integrated in the innerwall of the upper portion of the applicator (1) and is configured to indirectly deliver the blue photons substantially from above the eyes of the human subject.
22. The applicator (1) according to claim 20 or 21 , wherein the at least one light guiding element (25, 25’, 26, 26’, 50) is reflective, optionally the at least one light guiding element (25, 25’, 26, 26’, 50) comprises a whitening agent.
23. The applicator (1) according to any one of the claims 20 - 22, wherein at least one light source (51 , 53, L, L’) is positioned at one end (27, 29) of the at least one light guiding element (25, 25’, 26, 26’, 50), preferably at least one light source (51 , 53, L,L’) is positioned at both ends (27, 29) of each of light guiding element (25, 25’, 26, 26’, 50).
24. The applicator (1) according to any one of the claims 20 - 23, wherein the at least one light guiding element (25, 26, 50) comprises at the bottom side (61) a protrusion (59) extended below facing towards the eye of the human subject, when wearing the applicator (1), or wherein the at least one light guiding element (25’, 26’) comprises at the bottom side (70) a protrusion extended below facing away from the eye of the human subject, when wearing the applicator (1).
25. The applicator (1) according to claim 24, wherein the protrusion (59) is positioned towards the eye of the human subject at an angle a with respect to the surface of the at least one light guiding element (25, 26, 50), wherein the angle a ranges from 0° to 70° or 15° - 50°, wherein the protrusion at the bottom side (70) is positioned away from the eye of the human subject atan angle a with respect to the surface of the at least one light guiding element (25’, 26’), wherein the angle a ranges from 0° to 70° or 15° - 50°.
26. The applicator (1) according to any one of the claims 20 - 25, wherein the at least one light guiding element (25, 25’, 26, 26’, 50) further comprises notches (55) extending along at least a part of the upper side (57) thereof in between two flat-portions of the upper side (57).
27. The applicator (1) according to claim 26, wherein the notches (55) are oftriangular cross-section where each notch has a center (63) which are equally distant from each other.
28. The applicator (1) according to any one of the claims 26-27, wherein the depth of the center (63) of notches are increasing towards the at least one end of the notches (55), preferably the depth of the center (63) of notches are increasing towards the end positioned next to the legs (7a, 7b) of the applicator (1).
29. The applicator (1) according to any one of the claims 19 - 28, wherein the applicator (1) comprises a frame-like structure (5) which forms an opening (3a’, 3b’) below the upper portion (23) of the support frame (9) and encloses only partially the perimeter of said opening(s) (3a’, 3b’) positioned in front of the eyes of the human subject when wearing the applicator (1).
30. The applicator (1) according to claim 29, wherein the frame-like structure (5) has inner sidewalls (16, 38) located below the at least one light guiding element (25, 25’, 26, 26’, 50) and said inner side-walls (16, 38) are reflective.
31. The applicator (1) according to any one of the claims 19 - 30, wherein the applicator (1) further comprises a lower portion (39) connected to the frame-like structure (5) and upper portion (23) of the support frame (9) of the applicator (1) wherein said lower portion entirely encloses the opening(s) (3a’, 3b’) positioned in front of the eyes of the human subject when wearing the applicator (1).
32. The applicator (1) according to claim 31 , wherein the lower portion (39) comprises a reflective surface which reflects the blue photons emitted from the blue light emitting composition and / or reflected from elsewhere to the eye of the human subject when wearing the applicator (1), optionally said lower portion (39) comprises a whitening agent.
33. The applicator (1) according to any one of the claims 30 - 32, wherein the reflective surface of the inner side-wall (38) and / or the lower portion (39) is positioned towards the eye of the human subject when wearing the applicator (1), at an angle B with respect to the horizontal-axis, wherein the angle B ranges from 0° to 70° or 15° - 50°.
34. The applicator (1) according to any one of the claims 29 - 33, wherein the frame-like structure (5) has sides (35, 36) facing the human subject when wearing the applicator (1), and inner surface (38) lining the opening(s) (3a’, 3b’); said sides (35, 36) and inner surface (38) being reflective.
35. The applicator (1) according to any of the claims 19 - 34, wherein the applicator (1) is configured for direct and / or indirect administration of blue photons from above to the retina of the eyes of the human subject wearing the applicator (1).
36. The applicator (1) according to any of the claims 19 - 35, wherein the applicator (1) is configured for direct and / or indirect administration of blue photons to the parafoveal area of the retina and / or the perifoveal area of the retina and / or the optic disc (‘blind spot’) of the eye of the human subject when wearing the applicator (1).
37. The applicator (1) according to any one of the claims 19 - 36, comprising the blue photon emitting composition, wherein the photon energy of the blue photons emitted by the composition is selected from the range 3,10 eV - 2,48 eV, or wherein the wavelength of the blue photons emitted by the composition is selected from the range 400 - 500 nm, or 440 - 490 nm, or 450 - 482 nm, or 460 - 480 nm, or 464 - 480 nm, or, 468 - 480 nm.
38. The applicator (1) according to any one of the claims 19 - 37, wherein the blue photon emitting composition emits blue photons with a M-EDI of 100 - 500 lux, or 150 - 400 lux, or 200 - 250 lux.
39. The applicator (1) according to any one of the claims 19 - 38, wherein the blue photon emitting composition is a LED selected from a semi-conductor composition selected from any of: gallium nitride (GaN);wide-gap ll-VI semiconductor such as zinc selenide (ZnSe);indium-gallium nitride (InGaN); andp / n semiconductor composition consisting of a p-layer and an n-layer, wherein the p-layer and the n-layer are both InGaN.
40. The applicator (1) according to any one of the claims 19 - 39, wherein the blue photon emitting composition is a LED that is a wide band-gap semi-conductor composition of the direct transition type with an energy band gap of 2.6 eV or larger.
41. Method of treating any one or more of non-motor symptoms in a human subject selected from:circadian rhythm disturbance;sleep disturbance during nighttime;sleepiness during daytime;tiredness during daytime;fatigue during daytime;depressed mood or depression;any combination of two - seven of these non-motor symptoms,wherein the method comprises the steps of (i) provision of a blue photon emitting composition of any one of the claims 1-18; and (ii) administration of a therapeutically effective amount of blue photons emitted by the blue photon emitting composition to the retina of the eye(s) of the human subject by administration of the blue photon emitting composition in the proximity of the eye of the human subject,therewith treating the one or more of non-motor symptoms in the human subject.
42. The method of claim 41 , wherein the human subject has any one or more selected from:(1) a jet lag due to time zone travelling;(2) having worked during nighttime or is working during nighttime;(3) a neu rod egene rative disorder;(4) Parkinson’s Disease (PD); or(5) any combination of (1) - (4).
43. Use of a blue photon emitting composition of any one of the claims 1-18 in the manufacture of a medicament for use in a method of treating any one or more of non-motor symptoms in a human subject:circadian rhythm disturbance;sleep disturbance during nighttime;sleepiness during daytime;tiredness during daytime;fatigue during daytime;depressed mood or depression;any combination of two - seven of these non-motor symptoms,wherein the method comprises the administration of a therapeutically effective amount of blue photons emitted by the blue photon emitting composition to the retina of the eye(s) of the human subject by administration of the blue photon emitting composition in the proximity of the eye of the human subject.
44. The use of claim 43, wherein the human subject has any one or more selected from:(1) a jet lag due to time zone travelling;(2) having worked during nighttime or is working during nighttime;(3) a neu rod egene rative disorder;(4) Parkinson’s Disease (PD); or(5) any combination of (1) - (4).
45. The blue photon emitting composition for use according to any one of the claims 1-18, or the method of claim 41 or 42, or the use of claim 43 or 44, wherein the blue photon emitting composition is provided by the applicator (1) of any one of the claims 19 - 40.
46. Kit of parts comprising the blue photon emitting composition of any one of the claims 1-18 or 45, or the applicator (1) of any one of the claims 19-40 or 45, and a leaflet with instructions for administering blue photons to the retina of the human subject by wearing the applicator (1) and therewith administration of the blue photon emitting composition in the proximity of the eye of the human subject, or with instructions for administration of a therapeutically effective amount of blue photons emitted by the blue photon emitting composition to the retina of the eye(s) of the human subject by administration of the blue photon emitting composition in the proximity of the eye of the human subject on the nose and ears of the human subject, for the treatment according to any one of the claims 1-18 or 41 -45.
47. The blue photon emitting composition for use according to any one of the claims 1-18 or 45, the method according to claim 41 or 42 or 45, or the use of claim 43 or 44 or 45, or the kit of claim 46, wherein:(i) the blue photons are administered to the ipRGC in the retina of the human subject substantially from above the eye(s) of the human subject; and / or(ii) the blue photons are administered to the eye(s) of the human subject indirectly by the blue photon emitting composition; and / or(iii) the blue photon emitting composition is administered to the eye(s) of the human subject by positioning the blue photon emitting composition in the proximity of the eye(s) of the human subject by wearing the applicator (1) of any one of the claims 19-40 on the nose and ears of the human subject; and / or(iv) the light emitted by the blue photon emitting composition has a wavelength of 460 - 480 nm; and / or(v) two daily doses of blue photons are administered to the human subject; and / or(vi) the first dose of blue photons administered during a day is administered to the human subject after awaking of the human subject in the morning, preferably within 0 - 60 minutes after awakening; and / or(vii) the second dose of blue photons is administered to the human subject at least 11 hours after administration of a first dose of blue photons, or 11-15 hours after administration of a first dose of blue photons; and / or(viii) the start of the dosing of the second administered dose of blue photons is no later than 2 hours before bedtime of the human subject; and / or(ix) the blue photons are dosed by administering the first dose and the second dose each to the retina of the eye(s) of the human subject by emission of blue photons by the blue photon emitting composition for a duration of 20 minutes - 90 minutes; and / or(x) the human subject sleeps during daytime after awakening in the morning for at most one time for 30 minutes or less; and / or(xi) the human subject sleeps during daytime after awakening in the morning for at most one time between noon and 2 p.m.; or any combination of (i) - (xi), or all of (i) - (xi).
